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Environmental And Genetic Influence On Cognition In Als-Ftd Spectrum Disease 
Abstract 
Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are earlier-onset, fatal 
neurodegenerative diseases that progressively rob affected individuals of their cognitive faculties and 
their ability to move freely, produce coherent speech, and be their former selves. Diagnosis precedes 
death by <10>years, and current interventions are limited to palliative or disease-slowing therapies. 
Recent seminal research has revealed that ALS and FTD are phenotypic extremes on a continuous 
spectrum with shared symptoms, pathobiology, and genetics. Despite increased knowledge of ALS-FTD 
spectrum disease, prognostication and therapeutic development are limited by immense phenotypic 
heterogeneity. One source of this heterogeneity is cognition: individuals across the ALS-FTD disease 
spectrum suffer varying degrees of decline in cognition due to neurodegeneration in the frontal and 
temporal lobes. Cognition is inextricably linked to functional ability and survival, and is thus a promising 
candidate for a prognostic marker and therapeutic target. With this in mind, the goal of my thesis work is 
to elucidate factors that influence the heterogeneity of cognitive impairment and corresponding 
frontotemporal neurodegeneration in ALS-FTD spectrum disease. I pursue this goal by studying clinical, 
demographic, genetic, anatomic, and biologic data from deeply-phenotyped patient populations and 
applying robust statistical approaches including multimodal, nonparametric, and machine learning 
analyses. My work demonstrates strong environmental and genetic contribution to cognition and 
frontotemporal disease anatomy in ALS-FTD spectrum disease, and suggests their importance to 
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Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are 
earlier-onset, fatal neurodegenerative diseases that progressively rob affected 
individuals of their cognitive faculties and their ability to move freely, produce 
coherent speech, and be their former selves. Diagnosis precedes death by <10 
years, and current interventions are limited to palliative or disease-slowing 
therapies. Recent seminal research has revealed that ALS and FTD are 
phenotypic extremes on a continuous spectrum with shared symptoms, 
pathobiology, and genetics. Despite increased knowledge of ALS-FTD spectrum 
disease, prognostication and therapeutic development are limited by immense 
phenotypic heterogeneity. One source of this heterogeneity is cognition: 
individuals across the ALS-FTD disease spectrum suffer varying degrees of 
decline in cognition due to neurodegeneration in the frontal and temporal lobes. 
Cognition is inextricably linked to functional ability and survival, and is thus a 
promising candidate for a prognostic marker and therapeutic target. With this in 
mind, the goal of my thesis work is to elucidate factors that influence the 
heterogeneity of cognitive impairment and corresponding frontotemporal 







 clinical, demographic, genetic, anatomic, and biologic data from deeply- 
phenotyped patient populations and applying robust statistical approaches 
including multimodal, nonparametric, and machine learning analyses. My work 
demonstrates strong environmental and genetic contribution to cognition and 
frontotemporal disease anatomy in ALS-FTD spectrum disease, and suggests 
their importance to advancements in clinical care and therapeutic development. 
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CHAPTER 1: INTRODUCTION 
 
In this chapter, I summarize prior scientific contributions to the study of factors 
influencing cognition in ALS-FTD spectrum disease. I begin by providing a broad 
overview of ALS-FTD spectrum disease with a focus on shared clinical, biologic, 
and genetic features. I then turn to the specific issue of heterogeneity in cognitive 
impairment, and review preliminary evidence for environmental and genetic 
influence on its presentation. I finally discuss how analytic approaches 
incorporating multimodal data sources and nonparametric and data-driven 
techniques can be used to study outstanding questions regarding environmental 
and genetic influence on cognition in ALS-FTD spectrum disease. 
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ALS-FTD SPECTRUM DISEASE 
 
Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are 
earlier-onset, fatal neurodegenerative diseases that progressively rob affected 
individuals of their cognitive faculties and their ability to move freely, to produce 
coherent speech, and to be their former selves. Diagnosis precedes death in 
typically less than ten years, and currently-available treatments are only palliative 
or serve to slow disease course. Historically, ALS and FTD comprised separate 
areas of research due to their respective neurological classifications as diseases 
of the motor system or of higher order cognition and behavior. These conditions 
are modernly thought of as two extremes on a continuous ALS-FTD disease 
spectrum rather than distinct neurodegenerative conditions due to seminal 
research from the past two decades demonstrating considerable overlap in 
clinical presentation, common underlying pathobiology and neuroanatomy, and 
shared genetic architecture. In this section, I will first briefly review the classic 
disease profiles of ALS and FTD, and then discuss key clinical, pathobiologic, 
neuroanatomic, and genetic evidence for the existence of these 
neurodegenerative conditions along a continuous disease spectrum. 
 
 
Disease Profile of ALS 
 
ALS, which is also referred to colloquially as Lou Gehrig’s disease in the United 
States and as motor neuron disease (MND) in the European Union, is 
characterized by progressive degradation of the voluntary motor system resulting 
in paralysis, and ultimately death. Symptom onset occurs from ages 40 - 70 but 
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is also noted in individuals in the 20s and 30s, and a recent meta-analysis found 
that 1.75 (1.55-1.96)/100,000 people per year worldwide are newly affected 
(Marin et al. 2017). Diagnosis requires clinically-evident symptoms of upper 
motor neuron (UMN) degeneration (e.g. spastic tone, deep tendon reflex) and 
clinical, neuropathological, or electrophysiological evidence of lower motor 
neuron (LMN) degeneration (e.g. weakness, muscle atrophy) (Brooks et al. 
2000). Symptoms can occur in bulbar or spinal musculature and on ipsilateral or 
contralateral sides of the body. Because ALS is a progressive disease and 
patients may come to clinical attention with a sub-clinical syndrome, the 
internationally recognized El Escorial criteria provide four categories of ALS 
based on diagnostic certainty: Suspected, Possible, Probable, or Definite ALS. 
Worsening of neuromuscular function over time is accompanied by progressive 
gray matter (GM) loss in the motor cortex and white matter (WM) degeneration in 
the corticospinal tracts and corpus callosum as evident through magnetic 
resonance imaging (MRI) and diffusion tensor imaging (DTI) (Foerster, Welsh, 
and Feldman 2013; Bede and Hardiman 2018), although extra-motor 
neurodegeneration is also observed. An estimated 10% of patients with ALS 
have a family history of disease often associated with a genetic mutation in 
C9ORF72 (Renton et al. 2011; DeJesus-Hernandez et al. 2011), SOD1 (D. R. 
Rosen et al. 1993), or TARDBP (Kabashi et al. 2008; Sreedharan et al. 2008); 
and a minority of patients (~10%) without a family history also have C9ORF72 
mutations (Taylor, Brown, and Cleveland 2016). Disease mechanism in patients 
with and without a genetic mutation is yet unknown; abnormal protein inclusions 
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composed of TDP-43 are found post mortem in ~97% cases, with the remaining 
showing fused in sarcoma (FUS) pathology associated with point mutations in 
the FUS gene (~1%) or showing superoxide dismutase pathology associated with 
point mutations in the SOD1 gene (Al-Chalabi et al. 2012). Death typically occurs 
20 - 48 months from initial symptom onset (Chiò et al. 2009), and is most 
frequently due to respiratory failure but can also result from other causes 
including cardiac failure (Corcia et al. 2008; Gil et al. 2008; D. R. Rosen et al. 
1993). Currently, Riluzole (brand name: Rilutek) and Edavarone (brand name: 
Radicava) are the only two treatments for ALS approved by the Food and Drug 
Administration (FDA), and have mild impact on disease course and nonspecific 
mechanisms of action. Riluzole targets excitotoxicity as a purported cause of 
neuronal death (Van Den Bosch et al. 2006), and its potential mechanisms of 
action include the inhibition of glutamatergic transmission, inactivation of voltage- 
gated sodium channels, and interference with events following transmitter 
binding at excitatory amino acid receptors (Doble 1996). Meta-analysis of four 
clinical trials indicate that Riluzole usage mildly prolongs survival by 2-3 months 
(R. G. Miller et al. 2007). The exact mechanism of action of Edavarone is also 
unknown, but its therapeutic effect of slowing the rate of progression of functional 
motor disability is attributed to its antioxidative properties (Cruz 2018; Abe et al. 
2014). Current clinical and preclinical therapeutic development for ALS includes 
highly-specific antisense oligonucleotide (ASO) therapies for patients carrying 
SOD1 mutation or C9ORF72 repeat expansion and formulation of viral therapies 
(Ly and Miller 2018). 
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Disease Profile of FTD 
 
Profound and worsening impairments in higher-order cognition, language, and 
social behavior comprise the predominant symptoms of FTD. FTD is named for 
the cerebral loci of neurodegeneration – in the frontal and temporal lobes - 
responsible for three main observed syndromes: behavioral variant FTD 
(bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent 
agrammatic primary progressive aphasia (naPPA). Each syndrome has its own 
diagnostic criteria, with executive deficits, personality change, and apathy 
characterizing bvFTD (Rascovsky et al. 2011), and discrete impairments in word 
comprehension and agrammatism characterizing svPPA and naPPA, 
respectively (Gorno-Tempini et al. 2011). The bvFTD syndrome is roughly four 
times more prevalent than naPPA or svPPA (Hogan et al. 2016). Age at 
symptom onset ranges from 21-80 years, with most cases occurring between 40- 
64, (Coyle-Gilchrist et al. 2016) and meta-analyses estimate incidence at 2.7- 
4.1/100,000 (Onyike and Diehl-Schmid 2013), making FTD the 2nd most common 
form of dementia among individuals less than age 65. Clinical FTD syndromes 
are distinguished by progressive patterns of atrophy observed through structural 
MRI (Meeter et al. 2017). Early atrophy in the orbital and dorsolateral prefrontal 
cortex, anterior cingulate cortex, and insula are observed in bvFTD (Pan et al. 
2012), whereas early atrophy in the left anteroinferior temporal lobe are observed 
in svPPA, and in the left inferior frontal cortex and insula in naPPA (Gorno- 
Tempini et al. 2004). All three syndromes feature progressive atrophy over 
disease course, with subcortical structures including the thalamus, basal ganglia, 
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and amygdala increasingly involved in bvFTD (Devenney et al. 2015), and 
increasing extent of left and right hemispheric atrophy in svPPA and naPPA 
(Rogalski et al. 2011; Bonner, Ash, and Grossman 2010; Grossman 2010). 
Around 30% of FTD patients have a family history of disease which can be 
largely attributed to pathogenic mutations in C9ORF72, MAPT, and GRN 
(Greaves and Rohrer 2019), although C9ORF72 mutations are also found in 
<10% of sporadic cases (Majounie et al. 2012). FTD is pathologically 
heterogeneous, and post-mortem study shows abnormal protein inclusions in the 
brain tissue composed of pathologic forms of TDP-43 in ~45-50% of cases, Tau 
in ~45% of cases, and fused-in-sarcoma (FUS) protein in <10% of cases (Irwin, 
Cairns, et al. 2014). The underlying pathologic protein can only be ascertained 
through association with a known pathogenic mutation (e.g. TDP-43 with 
C9ORF72) or, in mutation-negative cases, upon autopsy (Irwin, Cairns, et al. 
2014). Death can occur as rapidly as 2 years and as prolonged as 12 years after 
initial symptom onset (Coyle-Gilchrist et al. 2016). There is no FDA-approved 
therapy for FTD; current treatments are palliative in nature and include 
antidepressant and antipsychotic medications for symptom management (Boxer 
and Boeve 2007; Tsai and Boxer 2016). Current therapeutic development 
includes ASOs directed towards patients carrying C9ORF72 repeat expansions 
and MAPT mutations, adeno-associated virus (AAV) therapies directed towards 
patients carrying GRN mutations, and monoclonal antibodies (mAb) targeting 
pathologic Tau (Boxer et al. 2020). 
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Clinical Features of ALS-FTD Spectrum Disease 
 
While symptomatically distinct in canonical diagnoses, FTD and ALS co-occur 
and their considerable phenotypic overlap confers clinically-observable evidence 
for their existence along a continuous disease spectrum. Broad recognition of 
phenotypic overlap between ALS and FTD is noted in scientific and medical 
literature beginning in the 1980s and 1990s (Neary et al. 1990), however early 
case studies dating to the 1920s provide the first known descriptions of 
phenotypic overlap (Nitrini 2014). The earliest known report comes from France 
in 1921, and describes a male patient with ALS who developed impaired 
cognition late in disease course. Three years later, in 1924, Brazilian physicians 
described a 25 year-old female patient who exhibited "absolute indifference to 
everything around her" and whose “association of ideas was done extravagantly" 
– now recognized as symptoms of apathy and executive dysfunction often 
observed in bvFTD; they further noted that her health declined before her death 
one year later, leaving her ultimately bed-ridden due to severe muscular atrophy. 
Contemporary population-based studies indicate 10-15% of patients with 
ALS meet criteria for a diagnosis of FTD and that nearly half manifest non- 
dementing impairment in cognition and/or behavior consistent with extra-motor 
frontal and temporal lobe neurodegeneration (Montuschi et al. 2015; Phukan et 
al. 2012; Elamin et al. 2013; Beeldman et al. 2016). Importantly, these 
impairments are not confounded by motoric disability, suggesting that 
neurological function beyond the motor system is affected in ALS. Point 
estimates of the proportion of the ALS patient population exhibiting behavioral 
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dysfunction and impairments in discrete cognitive domains have historically 
differed, due in part to the use of different neuropsychological screening tools. 
Current estimates have improved due to the use of a validated, now widely- 
accepted, screening instrument specifically designed to measure cognition, 
language, and behavior in the context of debilitating motor impairment which is 
inherent to ALS (Abrahams et al. 2014). Behavioral dysfunction occurs most 
frequently in ~40% of patients, and 20-30% of patients show executive, verbal 
fluency, and language impairments; impairments memory and visuospatial 
function are less common, affecting only 9-12% of patients (Crockford et al. 
2018). Importantly, comorbid FTD and the development of extra-motor 
impairments in cognition, language, and/or behavior in patients with ALS are 
associated with more accelerated functional decline (Elamin et al. 2013), 
advanced disease stage, (Crockford et al. 2018) and shorter survival (Elamin, 
Phukan, Bede, Jordan, Byrne, Pender, and Hardiman 2011a; Hu et al. 2013), 
relative to motor-only ALS. 
Relatively less is known about the development of ALS in patients with 
initial  FTD.  Population-based  studies  report  that  4-9%   of patients   with   
FTD develop symptoms of ALS (Rosso, Donker Kaat, et al. 2003; Mercy et al. 
2008; J. K. Johnson et al. 2005; Seelaar et al. 2007); however, few studies 
specify the degree of UMN and LMN involvement, and other clinical descriptors 
of ALS (e.g. site of symptom onset, El Escorial diagnosis) are lacking. A smaller 
cohort-based clinical study including 38 FTD patients reported higher 
percentages of FTD patients who also meet criteria for ALS (~13%) and a higher 
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percentage of patients with FTD who show clinical evidence of minor motor 
system dysfunction such as occasional fasciculations, mild wasting or weakness 
(~30%) (Burrell et al. 2011); these differing estimates likely reflect sample 
characteristics. Others have also reported similar proportions based on post 
mortem evidence of motor neuron degeneration in patients diagnosed with FTD 
during life (Josephs et al. 2006). 
Formal diagnostic categories for the co-occurrence of ALS and FTD were 
not established until 2013 with the so-called ‘Strong criteria’ for the diagnosis of 
frontotemporal cognitive and behavioral syndromes in ALS (Strong et al. 2009). 
Revised as of 2017 to incorporate additional language and social cognition 
deficits (Strong et al. 2017), the Strong criteria now include four syndromes 
collectively considered as ‘ALS frontotemporal spectrum disorder’: ALS- 
cognitively impaired (ALSci), ALS-behaviorally impaired (ALSbi), ALS-cognitive- 
behavioral impairment (ALSbci), and ALS-FTD. ALSci and ALSbi are diagnosed 
based on discrete impairments in cognition (including verbal fluency or at least 
two demonstrated executive or language impairments) or behavior (including 
apathy, or at least two other behavioral symptoms), respectively, whereas 
ALSbci captures individuals who fulfill criteria for both ALSci and ALSbi. The 
diagnostic category of ALS-FTD is more phenotypically heterogeneous, and 
applies to individuals with evidence of progressive deterioration of behavior or 
cognition who also have either 1) at least three behavioral or cognitive symptoms 
of bvFTD, 2) at least two behavioral or cognitive symptoms of bvFTD together 





No distinct classification criteria exist for motor neuron degeneration 
symptoms in the context of FTD, and El Escorial classification is applied as for 
patients with initial ALS. The labels ‘ALS-FTD’, FTD with motor neuron disease 
(FTD-MND), and FTD-ALS are all used in the literature to categorize patients 
with initial FTD who also show symptoms of ALS; here, I will use the term FTD- 
ALS to denote this category of patients. This term inherently describes a 
heterogeneous group of patients who may have initial bvFTD, naPPA, or svPPA 
followed by comorbid with symptoms of ALS, and indeed bvFTD-ALS, naPPA- 
ALS, and svPPA-ALS patients have all been clinically observed (Vinceti et al. 
2019; Coon et al. 2011), although data on relative frequency are lacking. There is 
evidence of motor phenotype and survival differences between FTD-ALS 
phenotypic subgroups, such that in one study, language-dominant FTD-ALS was 
associated with bulbar-onset motor symptoms and shorter survival in comparison 
with bvFTD-ALS (Coon et al. 2011), consistent with shorter survival from 
symptom onset in bulbar-onset ALS (Chiò et al. 2009). 
 
 
Common Pathobiology of ALS-FTD Spectrum Disease 
 
Patterns of neurodegeneration in ALS and FTD reflect differences in motoric, 
cognitive-behavioral, and blended phenotypes, but typically involve a common 
pathologic substrate and overlap in affected neuroanatomic regions link the two 
diseases in pathobiology. 
ALS and FTD frequently share a common underlying proteinopathy, with 
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cytoplasmic inclusions predominantly composed of TDP-43, an acronym for 
transactive response DNA-binding protein – 43 kiloDalton, found in ~97% of ALS 
and ~50% of FTD cases post mortem (Neumann et al. 2006; Arai et al. 2006). 
TDP-43 is encoded by the TARDBP gene on chromosome 1 and is ubiquitously 
expressed in tissues throughout the body. In its non-pathologic state, TDP-43 is 
localized to the nucleus where it serves to regulate transcription, stabilize RNA, 
and process mRNAs for alternative splicing (Ratti and Buratti 2016). Researchers 
have also demonstrated a role for TDP-43 in axonal outgrowth with particular 
implications for motor neuron development (Fallini, Bassell, and Rossoll 2012). 
Pathologic TDP-43 differs from normal TDP-43 in that it is mislocalized from the 
nucleus to the cytoplasm, undergoing hyperphosphorylation and – in most, but 
not all (E. B. Lee et al. 2017), cases – ubiquitination, which encourage its affinity 
to aggregate into abnormal inclusions (Buratti and Baralle 2012). The exact 
pathomechanism of TDP-43 inclusions is debated (E. B. Lee, Lee, and 
Trojanowski 2011), and evidence for both loss of function and gain of function 
mechanisms has been presented (Hergesheimer et al. 2019). 
Though its pathomechanism remains unknown, TDP-43 pathology 
demonstrates a key role in the neurodegenerative phenotypes across the ALS- 
FTD disease spectrum. TDP-43 pathology is specified into five subtypes (A, B, C, 
D, and E) based on ubiquitination, cortical distribution, and neuronal morphology, 
and each subtype corresponds to particular clinical syndromes (Mackenzie et al. 
2011; Mackenzie and Neumann 2017; E. B. Lee et al. 2017). For example, Type 
A pathology features many neuronal cytoplasmic inclusions (NCIs) and short 
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dystrophic neurites (DNs), predominates in cortical layer II, and is most 
commonly observed in bvFTD and naPPA phenotypes (Mackenzie et al. 2011). 
Type B pathology features moderate NCIs, few DNs, and distribution across all 
cortical layers (Mackenzie et al. 2011). Type B pathology predominates in ALS 
and in FTD with motor neuron degeneration, leading some to propose subtype 
specification as an account for clinical overlap between ALS and FTD (Burrell et 
al. 2016). 
Disease staging systems for TDP-43 pathology in ALS and bvFTD 
demonstrate neuroanatomic overlap in disease vulnerability and suggest the 
sequential spread of pathology. In a pathological staging system based on post 
mortem study of 39 bvFTD cases, TDP-43 pathology is proposed to disseminate 
from the orbital frontal cortex, gyrus rectus, and amygdala caudally to the motor 
cortex, and – most rarely - the visual cortex (Brettschneider et al. 2014). In a 
similar staging system in 76 ALS cases, TDP-43 pathology is proposed to 
disseminate sequentially from the motor cortex, brainstem motor nuclei, and 
spinal motor nuclei rostrally to the prefrontal and temporal cortices, with rare 
involvement of the hippocampus (Brettschneider et al. 2013); others have 
additionally shown that extra-motor pathologic burden is more severe in cases 
with clinical phenotypes of ALS-FTD and ALSci relative to ALS (Prudlo et al. 
2016). The sequential involvement of anatomic regions itself suggests a 
pathologic ‘spread’ underlying the course of ALS-FTD spectrum disease, and in 
vitro and non-human studies indeed suggest evidence of cell-to-cell spread of 
pathologic TDP-43 aggregates (Braak et al. 2013). Isolated pathologic 
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aggregates spread cell-to-cell in vitro in a prion-like manner (Feiler et al. 2015; 
Nonaka et al. 2013), and introduction of human pathologic TDP-43 in a mouse 
model recapitulates sequential staging seen in human studies (Porta et al. 2018). 
Together with staging studies in humans, this research indicates similar 
vulnerability of the motor, frontal, and temporal cortices to TDP-43 pathology 
across the ALS-FTD spectrum in an anatomically contiguous manner. 
 
 
Shared Genetic Architecture of ALS-FTD Spectrum Disease 
 
In addition to overlapping clinical phenotypes and common pathobiology, FTD 
and ALS are further linked through a shared genetic architecture. This complex 
architecture features pathogenic mutations occurring in familial and sporadic 
forms of disease, as well as susceptibility loci that confer increased risk of ALS- 
FTD spectrum disease including in cases negative for pathogenic mutations. 
Before discussing pathogenic mutations and risk factors in the ALS-FTD 
spectrum, it is necessary to clarify some key terminology. ‘Familial’ refers to the 
occurrence of a disease in an individual with a family history of that, or a similar, 
disease, and ‘sporadic’ refers to the occurrence of a disease in an individual with 
no known family history. The distinction between familial and sporadic disease 
may be subject to ascertainment bias due to differences in history-taking or 
applied family pedigree criteria (Turner et al. 2017). An estimated 30% of FTD 
cases and <10% of ALS cases occur in individuals with familial disease (Ferrari, 
Manzoni, and Hardy 2019), with the remainder classified as apparent sporadic. 
The phrases ‘familial disease’ and ‘genetic disease’ are often conflated in the 
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literature, as the majority of familial disease can be attributed to a known 
pathogenic mutation inherited in a Mendelian fashion. However, pathogenic 
mutations can also occur in individuals with sporadic disease (i.e. no family 
history of disease). The term ‘pathogenic’ is used to describe genetic mutations 
that are capable of causing disease, whereas susceptibility loci describe allelic 
variations that are associated with disease but not (or not yet) causally linked to 
disease incidence. These loci are typically identified through genome-wide 
association studies (GWAS), and in many cases consist of single base-pair 
changes in the genome called single nucleotide polymorphisms (SNPs). 
Pathogenic mutations in the same genes are found in individuals with 
FTD, ALS, and blended ALS-FTD spectrum phenotypes. Interestingly, 
pathogenic mutations in TARDBP - the gene encoding TDP-43 - are rare (Van 
Deerlin et al. 2008; Kabashi et al. 2008), observed in an estimated <1% of 
familial and sporadic ALS (Turner et al. 2017) and even less frequently in  
patients with FTD (Benajiba et al. 2009; Caroppo et al. 2016). Hexanucleotide 
(GGGGCC) repeat expansions in the noncoding promoter region of C9ORF72 on 
chromosome 9 are the most common genetic cause of both familial and sporadic 
forms of disease across the ALS-FTD spectrum (Renton et al. 2011; DeJesus- 
Hernandez et al. 2011). A 2012 study of 4448 patients with ALS and 1425 
patients with FTD reported that 37.6% of familial ALS and 25.1% of familial FTD 
harbor C9ORF72 mutations, and that 7% of sporadic ALS and 6% of sporadic 
FTD patients harbor C9ORF72 mutations (Majounie et al. 2012). Translation of 
the hexanucleotide repeat yields five forms of dipeptide repeat proteins (DPRs) 
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that aggregate to form intracellular inclusions (Mori et al. 2013), and have 
demonstrated neuronal toxicity (Freibaum and Taylor 2017). Moreover, 
C9ORF72 repeat expansions are causally associated with TDP-43 pathology 
(Chew et al. 2015), and aggregated DPRs both induce and are induced by 
intracellular aggregation of phosphorylated TDP-43 (Nonaka et al. 2018; 
Solomon et al. 2018), suggesting a cumulatively synergistic pathology. 
Several additional - although rare - pathogenic mutations in other genes 
have also been causally associated with ALS, FTD, and blended ALS-FTD 
spectrum phenotypes. These include mutations in coding for proteins including 
sequestosome-1 (SQSTM1) (Le Ber et al. 2013), ubiquilin-2 (UBQLN2) (Synofzik 
et al. 2012), optineurin (OPTN) (Pottier et al. 2015), coiled-coil-helix coiled-coil- 
helix domain containing 10 (CHCHD10) (Bannwarth et al. 2014), TANK binding 
kinase 1 (TBK1) (Freischmidt et al. 2015), dynactin-1 (DCTN1) (Münch et al. 
2005), cyclin-F (CCNF) (Williams et al. 2016), and TIA1 (TIA1) (Mackenzie et al. 
2017). Interestingly, these rare mutations offer additional genetic insight into 
molecular mechanisms of ALS-FTD spectrum disease and implicate cellular 
waste disposal pathways, immune system signaling, and gene expression 
regulation (Ferrari, Manzoni, and Hardy 2019). 
Susceptibility loci further suggest shared genetic architecture along the 
ALS-FTD disease spectrum. Many case-control GWAS have been separately 
performed in ALS (Nicolas et al. 2018; van Es et al. 2009; van Es et al. 2007; van 
Rheenen et al. 2016) and in FTD (Ferrari et al. 2014; Ciani et al. 2019). One 
GWAS from 2010 focused on ALS-FTD disease spectrum phenotypes with 
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confirmed TDP-43 pathology (N=515) and identified multiple SNPs near 
TMEM106B mapping to a single linkage disequilibrium block on 7p21 (Van 
Deerlin et al. 2010); however, this study was restricted to unrelated individuals 
with mutations in GRN. A recent repeat of this GWAS approach in 517 unrelated 
Caucasian patients who screened negative for GRN and other pathogenic 
mutations associated with ALS-FTD spectrum disease identified additional SNPs 
near C9ORF72, UNC13A, DPP6, and HLA-DQA2 (Pottier et al. 2019). A joint 
meta-analysis of public GWAS data from 4,377 ALS patients and 435 pathology- 
proven FTD patients with TDP-43 also demonstrated shared genetic risk across 
the ALS-FTD spectrum at SNPs near UNC13A and SPG8, with p values for the 
locus near UNC13A increasing in significance after conditioning on C9ORF72 
(Diekstra et al. 2014). More recently, novel approaches incorporating genome- 
wide conjunction and conditional analyses studied the joint association between 
discrete phenotypes along the ALS-FTD spectrum (ALS, FTD with TDP 
pathology, sporadic FTD) and additional neurodegenerative phenotypes 
(Alzheimer disease, corticobasal degeneration, Parkinson disease, and 
progressive supranuclear palsy) (N=124,876), conditioning p values for identified 
loci based on shared association with two or more phenotypes (Karch et al. 
2018). Over 20 loci were identified, including at known loci (e.g. near UNC13A 
and C9ORF72) and at novel loci (e.g. near NSF and ERGIC1). Additional 
approaches further suggest that susceptibility loci may contribute to the genetic 
architecture underlying the ALS-FTD spectrum disease in a polygenic manner, 
though this was demonstrated in a population of healthy individuals from the UK 
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Biobank study (Hagenaars et al. 2018). 
 
 
Neuroanatomy of ALS-FTD Spectrum Disease 
 
The lack of current neuroimaging biomarkers for TDP-43 pathology precludes 
study of its anatomic distribution in vivo (Feneberg et al. 2018), but MRI and DTI 
enable the in vivo study of neurodegeneration across the ALS-FTD spectrum and 
suggests similar anatomic overlap as seen in post mortem study of TDP-43 
pathology. Cross-sectional studies of patients grouped by diagnosis recapitulate 
known disease neuroanatomy associated with ALS and FTD phenotypes (Omer 
et al. 2017), and demonstrate anatomic overlap in the orbitofrontal and anterior 
cingulate cortices, corticospinal tracts, and corpus callosum including between 
ALS patients without clinically-evident cognitive impairment and bvFTD patients 
(Crespi et al. 2018; Ferraro et al. 2018). Blended ALS-FTD disease spectrum 
phenotypes (e.g. ALS-FTD, ALSci, FTD-ALS) show more extensive 
neurodegeneration relative to discrete ALS or FTD syndromes. For example, one 
recent study of ALS in the context of language-variant FTD observed left 
precentral gyrus GM atrophy in patients with naPPA-ALS in addition to canonical 
naPPA-associated atrophy in the left inferior frontal gyrus, pars opercularis and 
triangularis, and left temporal pole (Vinceti et al. 2019). ALSci and ALS-FTD 
patients show increasing extramotor GM neurodegeneration in regions including 
the inferior, middle, and superior temporal gyri, orbitofrontal cortex, superior 
frontal gyrus, anterior cingulate cortex, and insula relative to frank ALS (Schuster 
et al. 2014; Agosta et al. 2016), and WM damage extending beyond the 
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corticospinal tracts and corpus callosum to include the uncinate and superior 
longitudinal fasciculi (Sarro et al. 2011; Agosta et al. 2016). 
MRI-based disease-staging systems and longitudinal neuroimaging 
provide perhaps the most approximate insight into the spread of ALS-FTD 
spectrum disease in vivo. DTI data from patients with ALS and from patients 
bvFTD have been staged cross-sectionally and longitudinally according to 
severity and extent of WM neurodegeneration and confirm anatomic patterns of 
TDP-43 pathology staging systems (Kassubek, Müller, Del Tredici, Lulé, et al. 
2018; Kassubek, Müller, Del Tredici, Hornberger, et al. 2018; Kassubek et al. 
2014; Müller and Kassubek 2018). Others have staged cross-sectional 
multimodal imaging data with neuropsychological evaluation to demonstrate 
sequential cognitive involvement corresponding to GM and WM 
neurodegeneration in ALS, suggesting earlier-stage involvement of the middle 
frontal cortex relating to executive impairment (Lulé et al. 2018). Longitudinal 
study of GM atrophy in ALS, while inherently limited by shorter patient survival, 
demonstrates progressive degeneration extending from the motor cortex rostrally 
and inferiorly into frontotemporal regions, and to the thalamus and caudate 
bilaterally (Menke et al. 2014). In FTD, longitudinal study of patients grouped by 
clinical variant shows worsening of focal atrophy; for example svPPA show 
greater percent atrophy changes in the left inferior temporal lobe relative to 
bvFTD, whereas bvFTD show greater percent atrophy in the ventromedial 
prefrontal cortex relative to naPPA (Lu et al. 2013). 
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ENVIRONMENTAL AND GENETIC INFLUENCES ON COGNITION 
 
Though a phenotypic spectrum, shared pathobiology and neuroanatomy, and 
common genetic architecture demonstrate a robust link between ALS and FTD, 
considerable heterogeneity between affected individuals precludes prognosis 
and therapeutic development. One source of heterogeneity of particular clinical 
importance is in cognition. Across the ALS-FTD spectrum, presence and severity 
of impaired cognition is consistently linked to rapid functional decline (Elamin et 
al. 2013), greater extent and severity of frontotemporal neurodegeneration 
(Agosta et al. 2016), greater caregiver burden (Caga et al. 2019), and shorter 
survival (Elamin, Phukan, Bede, Jordan, Byrne, Pender, and Hardiman 2011a; 
Hu et al. 2013). In this section, I review existing evidence for influences of 
environmental and genetic factors on impaired cognition, and discuss key 





Environmental modifiers of disease refer to factors external to the individual that 
can influence facets of disease including incidence and phenotype. Numerous 
and diverse environmental factors have been associated incidence of ALS-FTD 
spectrum disease. These include the association of cigarette smoking, athletic 
activity, environmental toxin exposure, and military service with increased odds 
of ALS incidence (Sutedja et al. 2007; Veldink et al. 2005; Huisman et al. 2013; 
Weisskopf et al. 2005; Bozzoni et al. 2016), and traumatic brain injury with 
increased odds of FTD incidence in veterans (Kalkonde et al. 2012) and in 
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sporadic FTD (Rosso, Landweer, et al. 2003). However, in terms of cognition, 
identified environmental factors come from a narrower category and largely relate 
to cognitive engagement over the lifespan. 
The discovery of the relationship between cognitive engagement and 
cognitive impairment comes from research on Alzheimer’s disease dementia by 
Dr. Yaakov Stern, who coined this phenomenon ‘cognitive reserve’ (Stern 2002). 
In a seminal series of work published in the 1990s, Dr. Stern demonstrated that 
individuals with higher years of education or more cognitively-taxing occupations 
had more advanced stages of Alzheimer’s disease as measured by rate of 
memory decline (Stern et al. 1999), temporoparietal blood perfusion seen 
through PET imaging (Stern et al. 1994), and survival (Stern et al. 1995). This led 
to the theory that cognitively-stimulating lifetime experiences like education may 
provide a ‘reserve’ that compensates for the neuropathological changes of 
Alzheimer’s disease, thus delaying the onset of clinical manifestation. Both 
functional and biologic mechanisms have been proposed to underlie 
observations of cognitive reserve. Functional accounts posit that increased 
frontal executive resources cultivated through lifetime cognitive engagement 
allow compensation for medial temporal lobe disease. Neuroimaging studies are 
most often cited as supporting functional accounts of cognitive reserve, and 
include reports of increased frontal connectivity in highly-educated individuals 
associated with attenuated memory decline, brain hypometabolism, and 
hippocampal volume loss (Franzmeier et al. 2017; Pudas et al. 2018). Biologic 
accounts referred to in the literature as ‘brain reserve’ propose that 
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neuroanatomic differences might also underlie observations of cognitive reserve. 
In support of this, one study in healthy elderly individuals demonstrate greater 
frontoparietal GM volume related to higher levels of education (Solé-Padullés et 
al. 2009). 
Evidence for cognitive reserve has been also observed in FTD, but differs 
in manifestation from Alzheimer’s disease. Primary atrophy in the frontal and 
temporal lobes characterizes disease phenotypes across the ALS-FTD spectrum, 
inherently compromising access to proposed frontal executive resources 
hypothesized to facilitate functional compensation for neurodegeneration in 
classic accounts of cognitive reserve. Research in patients with bvFTD supports 
this idea, as more cognitively-demanding premorbid occupational status relates 
to more rapid decline in executive function but not in semantic memory, a 
cognitive domain that is relatively spared in patients with bvFTD (Massimo et al. 
2019). Both higher occupational and educational attainment relate to lower 
cerebral blood flow (Borroni et al. 2009) and lower glucose metabolism (Spreng 
et al. 2011; Perneczky et al. 2007) in the frontal cortex in patients with bvFTD, 
demonstrating compromised frontal lobe activity. Furthermore, cognitive 
engagement is differentially associated with survival in FTD compared to 
Alzheimer’s disease, with more cognitively-demanding premorbid occupation 
relating to longer survival from symptom onset in bvFTD but shorter survival from 
symptom onset in Alzheimer’s disease (Massimo et al. 2015). 
While prior research has identified cognitive engagement as an 
environmental contributor to cognitive impairment, several limitations necessitate 
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further study to understand its influence in the ALS-FTD disease spectrum. First, 
prior research on cognitive reserve in ALS-FTD spectrum disease have been 
limited to a single phenotype – bvFTD – and explicitly excluded individuals with 
motor symptoms. Thus, it is yet unknown whether this phenomenon extends to 
influence cognition in patients with other ALS-FTD spectrum phenotypes 
including ALS-FTD, svPPA, and naPPA. Furthermore, prior studies have not yet 
explored structural brain integrity, or how cognitive reserve may mediate the 
relationship between brain structure and cognitive impairment. These lead to the 
following unanswered question in environmental influence on cognition in ALS- 
FTD spectrum disease: how does cognitive reserve relate to structural 
neuroanatomy and cognitive impairment in heterogeneous phenotypes across 





Prior discussion of genetics in this introduction largely related to the incidence of 
disease; however, accumulating evidence suggests genetic influence on 
phenotypic heterogeneity in ALS-FTD spectrum disease. This includes earlier 
age at disease onset, more rapid symptom progression, and shorter survival in 
C9ORF72 mutation carriers relative to non-carriers (Byrne et al. 2012; Suh et al. 
2015; Umoh et al. 2016; Irwin, McMillan, et al. 2014; Moore et al. 2020), and in 
patients screening positive for SNPs near UNC13A (Chiò et al. 2013). Additional 
evidence suggests that the relationship between genetics and phenotypic 
heterogeneity in ALS-FTD spectrum disease extends to cognition and implicates 
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both pathogenic mutations and SNPs. 
 
In the context of ALS-FTD spectrum disease, the majority of research on 
genotype-phenotype relationships in cognition has been focused on C9ORF72. 
First, in addition to causal association with frank ALS, frank FTD, and varied 
phenotypes along the ALS-FTD disease spectrum, C9ORF72 mutations increase 
the likelihood that an ALS patient will develop symptoms of FTD. One population- 
based study in the US (N=781) reported behavioral symptoms of FTD in 14.8% 
of ALS patients who were carriers compared to only 1.7% of non-carriers (Umoh 
et al. 2016), whereas another population-based study in Ireland (N=191) reported 
behavioral symptoms in 50% of carriers compared to 12% non-carriers (Byrne et 
al. 2012). C9ORF72 mutations are also linked to rate of cognitive decline across 
the ALS-FTD spectrum, with one study showing more rapid decline on a verbal 
fluency measure of executive function (Irwin et al. 2013) and another showing 
more rapid decline in visuospatial and memory function in addition to executive 
function (Mahoney et al. 2012). Psychiatric symptoms have also been reported in 
C9ORF72 mutation carriers across the ALS-FTD disease spectrum (Snowden et 
al. 2012; Devenney et al. 2017). Neuroanatomic differences in C9ORF72 carriers 
relative to non-carriers are also widely observed both in vivo and post mortem. A 
comprehensive literature review conducted in 2015 show heterogeneity of 
findings across published studies of neuroimaging in C9ORF72 carriers likely 
due to differences in clinical phenotype and disease stage (Prado et al. 2015). 
However, studies accounting for these potential confounds show more extensive 
extramotor GM and WM degeneration particularly in frontotemporal regions in 
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ALS (Bede et al. 2013), which also correspond to cognitive impairment (Floeter 
et al. 2016). Post-mortem, C9ORF72 mutation carriers display TDP-43 pathology 
in the cerebellum and hippocampus, which are rarely observed in non-carriers 
(Mackenzie, Frick, and Neumann 2014). Interestingly, the associations between 
C9ORF72 mutation status, cognitive impairment, and neuroanatomic 
susceptibility appear to be epigenetically modulated: hypermethylation of the 
C9ORF72 promoter shows evidence of neuroprotection in terms of cognitive 
decline, MRI measures of structural brain integrity, and post-mortem 
neuropathologic burden (Russ et al. 2015; McMillan et al. 2015). 
A small, yet growing body of evidence demonstrates that genetic influence 
on cognition extends beyond study of known pathogenic mutations to also 
include susceptibility loci. These include quantitative trait loci (QTL) analyses that 
probe the association between a genetic locus and variation in a continuous, 
rather than binary (e.g. having disease vs. not having disease), disease trait. A 
SNP near TMEM106B originally identified as a susceptibility locus for TDP-43 
pathology in GRN mutation carriers was found to relate to impaired cognition on 
a task of executive function in patients with ALS (Vass et al. 2011). In bvFTD 
patients, genotype-phenotype relationships are also observed. Risk genotype at 
a SNP near the MOBP gene was found to associate with more severe WM 
neurodegeneration in the corona radiata and superior and inferior longitudinal 
fasciculi, more severe GM neurodegeneration in the precuneus and superior 
temporal gyrus, and shorter survival from symptom onset in a mixed cohort of 
sporadic, mutation-negative bvFTD patients with underlying Tau and TDP-43 
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pathology (Irwin, McMillan, et al. 2014). In another study, SNPs near MAPT, 
GRN, SORT1, and MOBP related to distinct WM neurodegeneration in the 
superior longitudinal fasciculus and midbrain in sporadic, mutation-negative 
patients with varying ALS-FTD spectrum disease phenotypes (McMillan et al. 
2014). The majority of ALS-FTD spectrum disease occurs in the absence of a 
family history disease or known pathogenic mutation, suggesting that the 
susceptibility loci mentioned here, and others yet unexplored, may influence 
variance in dementia for a larger proportion of ALS-FTD spectrum disease. 
Here, I have discussed promising evidence for genetic influence on 
cognition in the ALS-FTD spectrum, yet much work in this area remains. The 
majority of prior work focuses on studies of individuals carrying C9ORF72 repeat 
expansions, and research in mutation-negative individuals is considerably less 
established. Many SNPs associated with incidence of ALS-FTD spectrum 
diseases have been identified, yet few have been studied in regards to 
quantitative or qualitative trait associations with cognition. Prior efforts to 
characterize the quantitative disease associations with single SNPs have been 
limited to the study of a single clinical phenotype or to the use of a single 
research modality, and potential polygenic contribution to cognition in ALS-FTD 
spectrum disease remains relatively unexplored. These lead to the following 
unanswered questions: Do SNPs associated with risk of ALS-FTD spectrum 
disease show quantitative-trait relationships with cognition and disease 
neuroanatomy? Do they do so in a polygenic manner? 
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MULTIMODAL, NONPARAMETRIC, AND MACHINE-LEARNING 
APPROACHES 
 
Thus far, I have described how ALS-FTD spectrum disease features complex 
overlap in clinical, neurobiologic, anatomic, and genetic characteristics. I have 
also reviewed prior literature in this field to identify outstanding research 
questions pertaining to how heterogeneity in the cognitive status of affected 
individuals may be shaped by environmental and genetic factors. In this section, I 
turn to discuss how these research questions can be addressed, focusing on 
multimodal, nonparametric, and machine learning approaches. 
Research employing multimodal data involves the collection and analysis of 
data from several, rather than single, sources. Deep phenotyping of patient 
populations with ALS-FTD spectrum disease requires data from multiple, diverse 
modalities, including clinical evaluation, demographic information, 
neuropsychological assessment, neuroimaging acquisition, genetic screening 
and genome sequencing, and post mortem neuropathologic analysis (Toledo et 
al. 2014). Each modality is able to characterize a specific and different facet of 
the disease process. For example, neuropsychological assessments are used to 
characterize and quantify cognitive impairment syndromes (Abrahams et al. 
2014; Strong et al. 2017), structural MRI reveals the anatomy of 
neurodegeneration underlying patient syndromes (Menke et al. 2017; Meeter et 
al. 2017), and neuropathologic and genetic study identify potential molecular 
causes and modifiers of disease (Neumann et al. 2006; Renton et al. 2011; 
DeJesus-Hernandez et al. 2011). The concurrent consideration of data from 
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multiple modalities allows for a characterization of disease that extends beyond a 
broad categorical diagnosis (i.e. clinical phenotype) to additionally describe the 
collection of the finest details about the condition (i.e. endophenotype) (Irwin, 
Cairns, et al. 2014). Multimodal approaches are critical to establish 
endophenotypes, for example, a patient with a clinical phenotype of ‘ALS’ could 
be endophenotyped as ‘a mutation-negative patient with sporadic ALS who has 
impaired executive function and structural MRI evidence of extramotor frontal 
lobe neurodegeneration’. Endophenotypes, in turn, are critical for the 
development and application of precision medicine therapies designed to target 
specific aspects of disease (e.g. ASOs designed to target C9ORF72 repeat 
expansions). 
In addition to enabling deep endophenotyping, multimodal data collection 
provides the opportunity to evaluate the reproducibility and robustness of 
research findings across complementary, yet distinct, datasets. Data collection 
from neurodegenerative patient populations suffers limitations in sample size and 
is often inconsistent in protocol across research centers, thereby precluding 
studies of direct reproducibility. Multiple modalities of data collected on the same 
patient cohort or, alternatively, different modalities of data collected on 
independent patient cohorts, offers a partial solution to this problem by increasing 
the number of datasets a researcher can study. With an increased number of 
datasets, researchers can assess the reliability of an observed effect and 
evaluate whether differing sources of data converge on a common finding (Bachli 
et al. 2020). For example, a genetic risk factor for cognitive impairment in ALS 
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might be further evaluated in relation to in vivo frontotemporal neurodegeneration 
through structural neuroimaging and post mortem burden of pathology. 
Irrespective of modality, data collected from patients often violate 
assumptions of statistical normality (e.g. homeoscedasticity) and thus make the 
use of parametric statistical methods inappropriate for their analysis (Pett 2015). 
Permutation-based tests are a class of nonparametric statistical methods that 
test the null hypothesis by calculating the probability of observing an outcome in 
the original data relative to random permutations of the data. Efficient 
permutation methods have been adopted for usage in healthcare datasets, 
including large and computationally-expensive neuroimaging and genetic 
datasets (Winkler et al. 2014; Conneely and Boehnke 2007). These methods 
have been previously employed to analyze both neuroimaging and genetic data 
from patients with ALS-FTD spectrum disease (McMillan et al. 2015; McLaughlin 
et al. 2017), suggesting their utility in further study of multimodal data from this 
patient population. 
In addition to nonparametric approaches, machine-learning has been 
employed in the study of neurodegenerative disease (Dinov et al. 2016; 
Hongming Li et al. 2019), including in bvFTD (Schroeter et al. 2014; Bachli et al. 
2020) and in ALS (Grollemund et al. 2019; Hothorn and Jung 2014). Machine 
learning uses computationally-powerful statistical techniques to make inferences 
and predictions from large datasets and techniques have been developed for use 
with single as well as multiple datasets (James et al. 2014). One machine 
learning technique developed for the analysis of multimodal data is sparse 
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canonical correlation analysis (sCCA). sCCA evaluates multivariate associations 
between two data sets while prioritizing sparsity by penalizing variables that 
contribute minimally to the statistical model (Witten, Tibshirani, and Hastie 2009; 
Witten and Tibshirani 2009). Importantly, variable selection from sCCA is data- 
driven in nature, chosen through analysis rather than by a researcher. Recently, 
sCCA was employed to identify SNPs associated with selective distributions of 
GM and WM disease in FTD patients (McMillan et al. 2014), and to identify 
compromised neuroanatomic networks related to executive, language, and 
behavioral phenotypes in patients with FTD (Avants et al. 2014). These prior 
studies suggest the utility of sCCA in further investigation of genotype-phenotype 
relationships in ALS-FTD spectrum disease. For example, this method could be 
used to evaluate multivariate relationships between patient genotypes (e.g. at 
SNPs) and performance on multiple neuropsychological measures of cognition. 
The aforementioned multimodal, nonparametric, and machine learning 
approaches are ideally suited to the study of environmental and genetic factors 
influencing heterogeneous cognitive phenotypes in the context of ALS-FTD 
spectrum disease. Multimodal data collection enables deep endophenotyping of 
patients including cognitive, anatomic, and genetic profiling, and allows the 
evaluation of candidate environmental and genetic modifiers across multiple 
datasets. Nonparametric analyses of these multimodal datasets (e.g. through 
computationally-efficient permutation methods) is essential, as observational 
patient data are demonstrably heterogeneous and often do not conform to 
theoretical distributions of statistical normality. Additionally, sCCA, a machine- 
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learning approach, can be used to integrate modalities into endophenotypes by 
identifying relationships in data-driven subsets of variables across large datasets 
of differing modalities, allowing for the exploration of multivariate relationships 
between cognition and environmental / genetic factors. With this suitability in 
mind, I combine multimodal, nonparametric, and data-driven approaches in the 
series of research studies comprising the subsequent chapters of this thesis with 
the goal of elucidating environmental and genetic influences on cognition in ALS- 
FTD spectrum disease in a statistically-robust manner. 
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OVERVIEW OF DISSERTATION STUDIES 
 
In this dissertation, I present three research studies evaluating how cognition in 
ALS-FTD spectrum disease is shaped by factors innate (i.e. genetic) and 
external (i.e. environmental) to affected individuals. I address the following 
specific questions: 
1. How does lifetime cognitive engagement relate to cognition and disease 
neuroanatomy in ALS-FTD spectrum disease? 
2. Do common genetic variants that confer risk for ALS-FTD spectrum 
disease relate to cognition and disease neuroanatomy? 
3. Is there evidence of polygenic contribution via common genetic variants to 
cognition and disease neuroanatomy? 
I address the first research question in an initial study investigating whether 
education and premorbid occupation level of patients with ALS-FTD spectrum 
disease relates to heterogeneity in cognition and neurodegeneration. I use a 
retrospective cohort design to study 55 patients and 90 controls with detailed 
demographic information, neuropsychological evaluation, and in vivo structural 
MRI from the UPenn Integrated Neurodegenerative Disease Biobank (Toledo et 
al. 2014). I include patients with genetic or autopsy confirmation of Tau or TDP- 
43 pathology in an effort to exclude dementia patients with underlying 
Alzheimer’s disease pathology, and – in an effort to capture the phenotypic and 
genetic heterogeneity of ALS-FTD spectrum disease – include patients ranging in 
clinical phenotype and genetic mutation status. To approximate cognitive 
engagement across the lifespan, I define a cumulative index of cognitive reserve 
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based on years of completed education and ordinal scoring of premorbid 
occupational complexity. I identify regions of gray matter atrophy from 
nonparametric permutation analyses of voxel-wise gray matter probability from 
T1-weighted MRI in patients relative to controls, and examine the relationship 
between the cognitive reserve index and severity of gray matter atrophy in 
identified regions in patients. I further examine how cognitive performance relates 
to both cognitive reserve index and to gray matter regions associated with the 
reserve index. Given the common frontal distribution of disease in ALS-FTD 
spectrum patients, I hypothesize that cognitive reserve relates to less atrophic 
frontal cortex gray matter and preserved performance on frontally-mediated 
neuropsychological measures. 
Next, in the second study, I investigate genetic influence on cognition and 
disease anatomy in ALS-FTD spectrum disease. Specifically, I test whether 
common genetic variation at rs12608932 (closest gene: UNC13A) – a locus that 
previously achieved genome-wide association with both ALS and FTD - further 
contributes to cognition, in vivo neurodegeneration, and post mortem pathologic 
burden. I again use a retrospective cohort design of 190 patients and 113 
controls from the UPenn Integrated Neurodegenerative Disease Biobank (Toledo 
et al. 2014), but focus my investigation here on patients with initial onset of ALS 
who also have sporadic and mutation-negative forms of disease. The 190 total 
patients studied describe two cohorts; one with T1-weighted structural MRI 
(N=109), a subset of whom also had neuropsychological evaluation (N=88), and 
another with post mortem tissue samples graded for TDP-43 pathology (N=102). 
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I additionally study 84 controls from the publicly-available Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) with genotyping at rs12608932 and T1-weighted 
MRI. I identify regions of cortical thinning from nonparametric permutation 
analyses of voxel-wise cortical thickness measurements in patients relative to 
controls, and examine the relationship between rs12608932 genotype and 
severity of cortical thinning in identified regions in patients and ADNI controls. I 
continue to evaluate rs12608932 genotype and study its relation to cognitive 
performance and to burden of TDP-43 pathology. Based on prior associations of 
rs12608932 and risk for ALS and FTD, and with reduced survival in ALS, I 
hypothesize that rs12608932 genotype associates with greater frontotemporal 
disease in ALS as evident in reduced cortical thickness in vivo, more impaired 
cognitive performance, and greater burden of TDP-43 pathology post mortem. 
Finally, in the third study, I build on prior evidence for single-allelic 
contribution to cognition and disease neuroanatomy from the second study to 
further evaluate potential polygenic contribution using a multivariate approach. I 
collaborate with investigators across institutions from the international Clinical 
Research in ALS and related disorders for Therapeutic Development (CReATe) 
Consortium to study an unprecedented cohort of 339 patients with longitudinal 
neuropsychological evaluation and genotyping at loci of common genetic 
variation that previously achieved genome-wide association with ALS or joint 
association with ALS and FTD. I use sCCA, an unsupervised machine learning 
approach, to identify a subset of loci that maximally contribute to cognitive 
heterogeneity in this cohort and derive a data-driven polygenic risk score for 
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impaired cognition from model estimates. I further evaluate this machine-learning 
derived polygenic risk score relative to anatomic disease burden in independent 
neuroimaging and autopsy cohorts from the UPenn Integrated 
Neurodegenerative Disease Biobank (Toledo et al. 2014). These include 114 
ALS patients and 114 controls with T1-weighted MRI and 88 ALS patients with 
post mortem tissue samples graded for TDP-43 pathology and neuronal loss. I 
hypothesize that the machine learning will reveal a subset of genetic loci 
associated with cognitive dysfunction profiles in ALS in a polygenic manner, and 
that follow-up analyses in independent neuroimaging and autopsy cohorts 
converge to characterize quantitative traits associated with polygenic risk from 
identified loci. 
Each study – though addressing a distinct and specific research question – 
shares the common goal of elucidating factors that modify cognition and disease 
anatomy in ALS-FTD spectrum disease. Critically, the environmental and genetic 
factors targeted in my research can provide novel and cost-effective biomarkers 
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In this study, we evaluate if cognitive reserve (CR) contributes to inter-individual 
differences in frontal gray matter (GM) and executive impairment that underlie 
heterogeneity in the disease course of confirmed frontotemporal lobar 
degeneration (FTLD) pathology. Fifty-five patients with autopsy confirmation or a 
pathogenic mutation consistent with underlying tau (FTLD-Tau) or TDP-43 
(FTLD-TDP) pathology and 90 demographically-comparable healthy controls 
were assessed with T1 MRI and neuropsychological measures (Mini  Mental 
State Exam, letter fluency, forward digit span, Rey complex figure, and Boston 
Naming Test). CR was indexed using a composite measure of education and 
occupation. We identified reduced GM density in FTLD patients relative to 
controls, ran regression analyses relating reduced GM density to CR index, and 
correlated regions of GM associated with CR with performance on 
neuropsychological measures. FTLD patients exhibited reduced bilateral 
frontotemporal GM relative to controls, consistent with the known anatomic 
distribution of FTLD pathology. CR index was positively associated with letter 
fluency and with GM density in right dorsolateral prefrontal cortex, orbitofrontal 
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cortex, rostral frontal cortex, and inferior frontal gyrus. Furthermore, letter fluency 
correlated positively with mean GM density in frontal GM regions associated with 
CR. Our results indicate that executive control and verbal ability assessed by 
letter fluency in FTLD is mediated in part by CR and frontal GM reduction. The 
identification of factors influencing cognitive and anatomic heterogeneity in FTLD 






Frontotemporal lobar degeneration (FTLD) is a pathologic spectrum of 
progressive neurodegenerative conditions affecting the frontal and temporal 
lobes that are associated with executive, social, and language impairments 
(Irwin, Cairns, et al. 2014). The disease course of FTLD is highly variable across 
individuals, including age at onset (J. K. Johnson et al. 2005), rate of decline 
(Josephs et al. 2011), and survival (Hodges et al. 2003). While some biologic 
mechanisms have been proposed to account for this heterogeneity (Gallagher et 
al. 2014; McMillan et al. 2015), environmental factors contributing to disease 
course remain obscure. 
Cognitive reserve (CR) theories suggest environmental factors including 
education and occupation provide a ‘reserve’ against the clinical manifestation of 
neurodegenerative disease despite significant pathological burden (Stern 2009). 
Individuals with high CR may compensate for dementia-associated 
neurodegeneration by increasing recruitment of frontal executive resources to 
improve cognitive performance and delay symptom detection (Kemppainen et al. 
2008; Bosch et al. 2010). In patients with FTLD, access to frontal executive 
resources is compromised early in disease course due to frontal tau or TDP-43 
pathology. Prior research on CR in FTLD-spectrum disorders is largely limited to 
behavioral variant frontotemporal dementia (bvFTD) patients with unconfirmed 
FTLD pathology, and has largely focused on brain metabolism and other 
functional measures (Perneczky et al. 2007; Borroni et al. 2009; Spreng et al. 
2011). There is a thus a need for investigation of CR in FTLD-spectrum patients 
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with confirmed FTLD pathology using structural measures of brain integrity. 
 
Recent evidence from autopsy-confirmed FTLD patients suggests that 
higher occupational attainment is associated with longer survival from symptom 
onset (Massimo et al. 2015). From this perspective, FTLD patients with higher 
occupational attainment may detect dementia symptoms earlier than lower 
occupational attainment patients because of their increased frontally-mediated 
work demands, therefore giving the impression that they are surviving longer. 
This is in contrast with traditional CR accounts based on Alzheimer’s disease 
(AD) that suggest that higher CR factors such as education and occupational 
attainment are associated with shorter survival. 
Critically, since AD has a neuroanatomic distribution of disease distinct 
from FTLD, including less frontal lobe disease, it is reasonable to speculate that 
CR may function differently in patients with FTLD. However, to our knowledge, 
the anatomic and cognitive profiles associated with CR in patients with confirmed 
FTLD remain unknown. Given the frontal distribution of disease in FTLD, we 
hypothesized that CR would be positively associated with frontal cortex grey 







We report 55 patients recruited from the Penn Frontotemporal Degeneration 
Center at the University of Pennsylvania and clinically diagnosed by a board- 
certified neurologist (M.G., D.I.) using published criteria for a clinical syndrome 
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associated with FTLD pathology (Gorno-Tempini et al. 2011; Rascovsky et al. 
2011; Armstrong et al. 2013; Strong et al. 2009). Inclusion criteria for this study 
required a post-mortem neuropathological diagnosis or genetic screening (see 
Neuropathological Diagnosis and Genetic Screening), an ante mortem T1- 
weighted MRI scan, neuropsychological assessment, and known occupational 
status and years of education. Patients’ clinical syndrome included behavioral 
variant FTD (bvFTD; N=34), amyotrophic lateral sclerosis (ALS) with FTD (ALS- 
FTD, N=7), nonfluent-agrammatic primary progressive aphasia (naPPA, N=6), 
corticobasal syndrome (CBS, N=4), semantic-variant primary progressive 
aphasia (svPPA, N=1) progressive supranuclear palsy (PSP, N=2), and ALS with 
mild cognitive impairment (ALS-MCI, N=1). Disease duration was defined as time 
of symptom onset, based on caregiver report of the earliest clinical feature, until 
time of MRI acquisition. Disease duration can alternatively be calculated as 
months between first diagnosis and clinical appointment and post hoc analyses 
confirm that we see similar results when using this calculation (all p<0.05). 
To identify regions of significant GM atrophy in FTLD (see below), we 
additionally recruited 90 demographically-comparable healthy controls who self- 
reported a negative history for neurologic or psychiatric disease, and completed 
an initial screening of Mini-Mental State Examination (MMSE)>27 (M. F. Folstein, 
Folstein, and McHugh 1975). Demographic features of FTLD patients and 
controls are summarized in Table 1. There were no significant differences in  
age, education, gender, or CR index (see below) between controls and patients 





Neuropathologic diagnoses of FTLD-Tau and FTLD-TDP were established 
according to consensus criteria (Mackenzie et al. 2010) by expert 
neuropathologists (J.Q.T.; E.B.L.) using immunohistochemistry with established 
monoclonal antibodies specific for pathogenic tau (mAb PHF-1) (Otvos et al. 
1994) and TDP-43 (mAbs p409/410 or 171) (Neumann et al. 2009), as previously 
reported (Toledo et al. 2014). Twenty patients had a primary FTLD-spectrum 
neuropathologic diagnosis at autopsy including corticobasal degeneration (CBD; 
N=2), PSP (N=5), Pick’s disease (N=3), referred to here collectively as FTLD-Tau 
disorders, or FTLD with TDP-43 inclusions (N=10), designated here as FTLD- 
TDP. Among those individuals with neuropathological confirmation of FTLD, five 





DNA was extracted from peripheral blood or brain tissue following the 
manufacturer’s protocols (Flexigene (Qiagen) or QuickGene DNA whole blood kit 
(Autogen) for blood, and QIAsymphony DNA Mini Kit (Qiagen) for brain tissue). 
Samples were genotyped for the C9ORF72 hexanucleotide-repeat using a 
modified repeat-primed polymerase-chain reaction and the MAPT (exons 1, and 
9-13), GRN (entire coding region), and TARDBP genes were sequenced to 
identify pathogenic mutations as previously described (Toledo et al. 2014). 
Sequencing data was analyzed using Mutation Surveyor software (Soft Genetics, 
State College, PA). Genetic screening revealed that a total of 40 patients (five 
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also with neuropathological confirmation) had a known pathogenic mutation 
associated with FTLD-Tau or FTLD-TDP disorders, including mutations in MAPT 
(N=7) (Hutton et al. 1998), as well as C9ORF72 expansions (N=20) (DeJesus- 
Hernandez et al. 2011; Renton et al. 2011) or mutations in the GRN (N=11) 




Standard Protocol Approvals, Registrations, and Patient Consents. 
 
All patients and controls participated in an informed consent procedure 




Cognitive Reserve Index. 
 
We assessed CR using a composite measure of education and occupation 
similar to previous reports (Borroni et al. 2009; Premi et al. 2013). Education was 
recorded in years and ranked with a score ranging from 1 to 4: (1) ≤12 years 
(primary or secondary education; N=13); (2) >12 and <16 (some post-secondary 
education; N=8); (3) 16 years (college education; N=11); and (4) >16 years 
(graduate education; N=23). Occupation was ranked on a 1-4 point scale based 
on US census categories: (1) Unskilled laborers (N=2); (2) Operative and service 
workers (N=5); (3) Managers, administrators, clerical and sales (N=20); (4) 
Professional and technical workers (N=28). We report a CR index as the sum of 





Neuropsychological assessment was performed within approximately two months 
from date of scan (M=2.20, SE=0.53; Range=0-16). Letter fluency is a measure 
of executive control and verbal ability and was assessed by the number of unique 
words beginning with “F” a patient was able to generate in one minute (excluding 
proper nouns and numbers) (Tombaugh, Kozak, and Rees 1999). The MMSE is 
a 30-point questionnaire that evaluates global dementia severity (Crum, Anthony, 
Bassett, and Folstein 1993a). Forward digit span, a measure of auditory-verbal 
short-term memory, was assessed with repetition of increasingly longer 
sequences until the patient erred; the maximum number of digits on a correct trial 
was recorded (Wechsler 2008). Rey figure copy, a measure of visuospatial 
constructional ability, required patients to copy a modified Rey complex figure 
and was scored for accuracy on a 12-point scale (Libon et al. 2011). The Boston 
Naming Test, a measure of confrontational word retrieval, required patients to 
orally name 30 line drawings; the total number of correct responses made  
without aid of a stimulus cue was recorded (Kaplan, Goodglass, and Weintraub 
2001). Forward digit span was unavailable for two patients, Rey copy was 
unavailable for five patients, and Boston Naming Test was unavailable for 11 
patients. 
In addition to reporting raw patient performance on neuropsychological 
assessments, we report the proportion of patients impaired on each task relative 
to published normative data of healthy controls matched to the mean age and 
mean education of our patients where available (Tombaugh, Kozak, and Rees 
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1999; Crum, Anthony, Bassett, and Folstein 1993a; Shirk et al. 2011); we report 
patient performance on Rey copy relative to normative data based on healthy 
controls recruited by the FTDC who were matched to the mean age and mean 
education of our patients (N=22 (50% Female); Age, years: M=61.81, SD=4.97; 
Education, years: M=15.73, SD=2.37). We defined patient impairment on each 
task as performance at or greater than 1.96 standard deviations, equivalent to 
p<0.05, below normative data from healthy controls. 
We used linear regression to relate performance on neuropsychological 
measures to CR index including age at assessment as a nuisance covariate. We 
report one-tailed p values as we predicted higher CR index to relate to better 
performance on neuropsychological measures. 
 
 
Neuroimaging Acquisition and Preprocessing. 
 
High-resolution T1-weighted MPRAGE structural scans were acquired using a 3T 
Siemens Tim Trio scanner with an 8-channel head coil, with T=1620ms, 
T=3.09ms, flip angle=15°, 192x256 matrix, and 1mm3 voxels. T1-weighted MRI 
images were then preprocessed using ANTs Cortical Thickness software 
(Tustison et al. 2014). Briefly, each individual dataset was deformed into a 
standard local template space in a canonical stereotactic coordinate system. 
Advanced Normalization Tools (ANTs) provides a highly accurate registration 
routine using symmetric and topology-preserving diffeomorphic deformations to 
minimize bias toward the reference space for computing the mappings and to 
capture the large deformation necessary to aggregate images in a common 
44 
 
space. Then, we used N4 bias correction to minimize heterogeneity (Tustison et 
al. 2010), the ANTs Atropos tool to segment images into six tissue classes 
(cortex, white matter, CSF, subcortical grey structures, brainstem, and 
cerebellum) using template-based priors and to generate probability maps of 
each tissue. GM probability images, the sum of the cortical, subcortical, and 
brainstem probability images, were then transformed into Montreal Neurological 
Institute (MNI) space, smoothed using a 2 sigma full-width half-maximum 





We used randomise software implemented in FSL to perform nonparametric, 
permutation-based statistical analyses (Winkler et al. 2014). Briefly, permutation- 
based statistical testing is robust to concerns regarding multiple comparisons 
since, rather than a traditional assessment of two sample distributions, this 
method assesses a true assignment of factors (e.g., group, CR index) to GM 
relative to many (e.g., 10,000) random assignments. We adopt a priori statistical 
thresholds consistent with similar prior reports that include FWE–correction for 
group comparison of GM (Ash et al. 2014), and to minimize Type II error (not 
observing a true regression result) we employ uncorrected p-values for GM 
regressions. 
Analysis 1. First, we evaluated regions of reduced GM in FTLD patients 
relative to controls using a nonparametric group comparison analysis. For this 
analysis we constrained analysis using an explicit mask that was restricted to 
45 
 
include only high probability GM (>0.5). We report clusters that survive a  
p<0.001 (FWE) threshold and cluster extent of >50 adjacent voxels relative to 
10,000 random permutations. 
Analysis 2. Second, we conducted two regression analyses to test 
whether CR index is associated with GM density in FTLD patients (Analysis 2a) 
and in healthy controls (Analysis 2b), and restricted both analyses to a mask 
defined by regions of reduced GM in patients relative to controls from Analysis 1. 
This mask was used so that we could focus our interpretation of CR in the 
context  of  GM  regions  affected by FTLD. Otherwise, it would be difficult to 
interpret how regions of GM that are not different from controls contribute to 
cognitive function in domains impaired in FTLD syndromes. Refer to Table 4 for 
whole-brain analyses that do not include an explicit mask of reduced GM density. 
We report clusters that survive a p<0.05 (uncorrected) threshold and 
cluster extent threshold of >50 adjacent voxels relative to 10,000 random 
permutations. Analysis 2a (FTLD patients) included disease duration and age at 
MRI as nuisance covariates, and Analysis 2b (healthy controls) included age at 
MRI as a nuisance covariate in an effort to control for factors associated with 
individual differences in GM but not specifically associated with CR. 
Analysis 3. In a third and final set of analyses, we used Pearson 
correlations to examine the relationship between regions associated with CR in 
FTLD patients and performance on neuropsychological measures. For each 
patient, we extracted the mean GM density in each region identified as 
associated with CR index from Analysis 2a. We then correlated mean GM 
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Patients demonstrated most impairment on letter fluency (70.91% impaired) 
consistent with compromised frontal resources relative to other domains 
including attention on forward digit span (18.87% impaired), visuospatial function 
on Rey copy (56% impaired), non-specific global cognitive impairment on MMSE 
(58.18% impaired), and language deficits on the Boston Naming Test (36.36% 
impaired) (Table 1). Regression analyses indicated that higher CR index was 
associated with better performance on letter fluency (95% CI=-0.015, 1.38; 
t=1.96, p=0.028), but not MMSE, forward digit span, Rey copy, or Boston Naming 





FTLD patients had reduced GM density relative to controls throughout bilateral 
frontal and temporal lobes, consistent with the known pattern of GM disease 
associated with FTLD pathology (Analysis 1, Table 2, Figure 1A). 
By restricting analysis to regions where patients exhibited reduced GM 
density relative to controls, we next found that CR index in patients was positively 
associated with GM density in right frontal cortex, including rostral, orbital, 
inferior, and dorsolateral prefrontal regions (Analysis 2a, Table 2, Figure 1B). 
47 
 
Thus, a patient with a higher CR index exhibited higher frontal GM density in 
these diseased regions in comparison to a patient with a lower CR index. We 
found no inverse association between CR index and GM density in any region of 
reduced GM density relative to controls (not shown). 
To examine the specificity of the relationship between CR index and GM 
density in FTLD, we performed a comparable analysis in controls restricted to the 
same GM regions as the regression analysis in patients. We found that CR index 
in controls was positively associated with GM density in the left inferior frontal 
gyrus only (Analysis 2b, Table 2, Figure 1C). 
In patients, frontal GM density related to higher CR index was also 
positively associated with performance on letter fluency (p<0.05), but not MMSE, 
forward digit span, Rey copy, or Boston Naming Test (all p>0.05) (Analysis 3, 
Table 3, Figure 2). This finding was anatomically specific such that regions of 
frontal GM density not related to CR were not associated with performance on 
letter fluency, or MMSE, forward digit span, Rey copy, or the Boston Naming 
Test (all p>0.05) (not shown). 
 
 
Post hoc Analyses. 
 
While our primary analyses use a CR index, we performed post hoc analyses to 
evaluate whether education and occupational attainment alone are similarly 
related to neuroimaging results (Table 5, Figure 3). These post hoc analyses 
largely converge with our CR index analyses: when considered separately, 
educational and occupational category are positively associated with GM density 
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in right frontal cortical regions similar to results obtained when using the CR 
index. Educational category also positively relates to GM density in the right 
caudate and left premotor cortex, and occupational category also positively 
relates to regions in bilateral temporal cortices and in the left frontal cortex. 
To evaluate whether right frontal GM density associated with CR is 
partially driven by sources of heterogeneity in our cohort we also performed post 
hoc logistic regression analyses evaluating neuropathological, genetic, and 
clinical subgroups. First, we observed that mean GM density in right rostral, 
orbital, inferior, and dorsolateral prefrontal regions were not significant predictors 
of tau versus TDP-43 pathological subgroups (all factors p>0.10). Second, we 
observed that each of these four GM regions also were not significant predictors 
of genetic mutation or sporadic forms of disease (all factors p>0.10). Last, we 
evaluated whether the four GM regions associated with CR were significant 
predictors of bvFTD clinical phenotype versus other phenotypes, since bvFTD is 
the predominant phenotype in our cohort. This analysis revealed that one region, 
right dorsolateral prefrontal cortex, (p=0.048) was more reduced in bvFTD 
relative to other phenotypes, however all remaining regions did not differ (all 
p>0.05). Together, these findings are suggestive that these sources of 






Our results suggest that CR contributes to inter-individual differences in reduced 
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frontal GM density and executive impairment that underlie heterogeneity in the 
disease course of FTLD. In an analysis restricted to frontal and temporal lobe 
regions of reduced GM density relative to controls, patients with higher CR 
exhibited higher GM density in right frontal cortical regions compared to patients 
with lower CR. Moreover, we demonstrate that regions related to CR in FTLD 
appear to be specific: CR in control participants was only related to higher GM 
density in the left IFG. In FTLD patients, higher frontal GM density in right frontal 
cortical regions was associated with superior performance on letter fluency, a 
neuropsychological measure of executive control and verbal ability indicative of 
frontal lobe integrity. These findings are consistent with a reserve model linking 
preserved frontal anatomic integrity and superior strategic processing to the 
prolonged survival of patients with FTLD who have higher education and 
occupational attainment (Massimo et al. 2015). 
Our findings are consistent with other evidence suggesting that CR is an 
environmental factor influencing the spectrum of disease in FTLD. Prior 
neuroimaging studies of behavioral bvFTD patients with unconfirmed FTLD 
pathology indicate CR may counteract the onset of dementia (Borroni et al. 2009; 
Perneczky et al. 2007; Spreng et al. 2011), while a recent survival analysis in 
patients with autopsy-confirmed FTLD pathology by our group indicates that 
higher occupational attainment is associated with prolonged survival from 
symptom onset (Massimo et al. 2015). These studies suggest that, despite the 
commonality of frontotemporal-predominant neurodegeneration, patients with 
FTLD appear to exhibit heterogeneous disease course that is determined in part 
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by environmental factors related to CR. It is imperative to identify and understand 
potential environmental contributors to the rate of decline in FTLD, as these may 
serve as prognostic markers and eventual therapeutic targets. 
Our analysis of CR in control participants demonstrates specificity of 
higher GM density in right frontal cortex associated with CR in FTLD patients. 
Several other studies have investigated CR in healthy controls, demonstrating a 
positive relationship between CR and structural brain integrity. For example, one 
study demonstrates that in healthy older controls, higher years of education are 
positively associated with GM volume in the superior temporal gyrus, insula, and 
anterior cingulate cortex (Arenaza-Urquijo et al. 2013). While we similarly found a 
positive association between CR index and GM density in the left IFG in our 
healthy control group, this region did not overlap with any region of higher GM 
density associated with higher CR index in our patient group. We interpret this to 
suggest that our findings of higher GM density associated with higher CR in the 
right rostral and orbital frontal cortex, dorsolateral prefrontal cortex, and inferior 
frontal gyrus are specific to FTLD patients. Future work is necessary to evaluate 
the potential role of left IFG in CR in healthy controls, but limited 
neuropsychological data in the current control cohort precludes our ability to 
evaluate the behavioral consequences of this association. 
To our knowledge, no prior studies have examined the association 
between CR and heterogeneity in neuroanatomical structure and cognitive 
function in patients with a clinical FTLD syndrome due to confirmed FTLD-Tau or 
FTLD-TDP pathology. Some studies report that patients with clinically diagnosed 
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FTD who have higher education and occupation exhibit evidence of greater 
frontal disease as measured by regional cerebral glucose utilization and regional 
cerebral blood flow (Borroni et al. 2009; Perneczky et al. 2007; Spreng et al. 
2011). These studies have been interpreted to suggest that CR confers 
compensatory benefit such that individuals with FTD who have higher CR can 
better withstand accumulating frontotemporal pathology than individuals with 
lower CR, and therefore delay symptom presentation. This resembles findings 
reported in Alzheimer’s disease (Kemppainen et al. 2008; Bosch et al. 2010). 
However, differences in patient population and study design necessitate cautious 
interpretation of these results. For example, as many as 16.7% of patients with 
FTD-related syndromes have AD neuropathology (Forman et al. 2006). 
Furthermore, the relationship between higher CR and greater frontotemporal 
pathology is difficult to interpret in this work in the absence of neuropsychological 
data. For example, it is unclear if for the same severity of frontotemporal 
pathology, FTD patients with higher CR demonstrate better cognitive or 
behavioral function than FTD patients with lower CR. Future research is needed 
to provide a more detailed assessment of how structural GM, functional imaging, 
and neuropsychological measures interact in the context of CR. 
Several mechanisms may underlie the association between higher CR 
index and higher right frontal cortex GM density and superior letter fluency in 
FTLD patients. One possible mechanism is inter-individual differences in genetic 
predisposition. For example, genetic studies in healthy twins suggest that there is 
a genetic contribution to normal variation in human cognitive function and brain 
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morphology, including frontal cortex GM volume (Pol et al. 2006). Another 
possibility is that higher frontal GM and superior cognitive function in FTLD 
patients with higher CR may be a function of earlier stages of disease. For 
example, patients with higher education and occupational attainment who are 
more dependent on frontally-mediated executive functions may be more sensitive 
to the emergence of cognitive difficulty, leading to clinical symptom detection at 
an earlier stage of disease. Either of these proposed mechanisms could result in 
patients with higher CR exhibiting relatively higher frontal GM and superior letter 
fluency compared to patients with lower CR. Longitudinal structural and  
functional neuroimaging and neuropsychological assessment in controls and 
FTLD patients are necessary to evaluate individual differences in rates of  
disease progression underlying heterogeneity in FTLD disease course related to 
education and occupation as proxies of CR. 
Our findings contribute to a growing body of evidence for factors thought 
to influence heterogeneity in FTLD disease course, and suggest the 
consideration of both biological and environmental factors. Others suggest that 
risk alleles in single nucleotide polymorphisms, including rs1768208 in myelin 
oligodendrocyte basic protein (MOBP) gene and rs1990622 in the TMEM106B 
gene (McMillan et al. 2014; Gallagher et al. 2014), are associated with greater 
pathology and earlier age of onset and death in FTLD. Moreover, recent 
evidence indicates that epigenetic factors like C9ORF72 promoter 
hypermethylation are associated with reduced neuronal loss and reduced GM 
atrophy in frontal cortex (McMillan et al. 2015). While genetic factors may 
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contribute to heterogeneity in the disease course of FTLD, our exploratory 
analyses suggest that genetic status is not a confounder of the current 
observations. Future research should investigate interactions between 
environmental factors, like CR, and biological factors, like genetics and 
epigenetics, on clinical heterogeneity in FTLD. 
Several potential caveats should be considered in the current study. We 
assessed CR using a composite index of education and occupation. While our 
observation that education and occupation independently also relate to right 
frontal GM, we also observed that each of these measures has some distinct 
frontal associations with GM. Future work evaluating the difference between 
these measures would be valuable. Moreover, future research should also 
consider other environmental factors implicated in CR such as midlife leisure 
activities (Scarmeas et al. 2001). Our patient cohort self-reported predominant 
white race and most received a college education; thus, more racially and 
educationally-diverse samples are needed in future studies of CR in patients with 
FTLD. Another caveat to consider is that the current study cohort included 
several different clinical phenotypes with a majority of our sample being 
comprised of bvFTD and the remaining consisting of primary progressive 
aphasias and movement disorders (e.g., CBS, PSP). While future research is 
necessary to stratify by clinical phenotype, our post hoc analyses suggested that 
only one GM region, right dorsolateral prefrontal cortex, was related to bvFTD. 
Importantly, regions implicated in CR that are most likely to be shared across 
clinical phenotypes, such as right inferior frontal gyrus, did not show differences 
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in GM density. Other sources of heterogeneity in our patient cohort including 
presence/absence of a genetic mutation and FTLD-Tau/FTLD-TDP pathology 
also did not appear to contribute to GM differences in regions related to CR, 
though future studies must address these distinct groups. 
With these caveats in mind, we conclude that CR is an environmental 
factor contributing to heterogeneity in executive control and verbal ability of 
patients with known FTLD pathology mediated by neuroanatomic structure. 
These findings stimulate investigation into additional environmental contributors 
to disease course, and suggest their importance in prognostic considerations and 
treatment trials in patients with FTLD. 
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Table 1. Mean (standard deviation) of frontotemporal lobar degeneration patient 
and control demographics and neuropsychological evaluation. 
 
 FTLD Controls 
N (F) 55 (20) 90 (40) 
Age, years 61.2 (8.07) 60.3 (8.65) 
Education, years 16.1 (3.11) 15.4 (2.49) 
Education, N per rank:   
1 13 14 
2 8 28 
3 11 27 
4 23 21 
Occupation, N per rank   
1 2 - 
2 5 13 
3 20 30 
4 28 47 
CR Index 6.14(1.79) 5.98 (1.55) 
MMSE (max=30) 23.36 (6.85) - 
Proportion impaired (%) 32/55 (58.18)  
Letter Fluency (words/min) 6.04 (4.72) - 
Proportion impaired (%) 39/55 (70.91)  
Forward Digit Span (# repeated) 5.17 (1.71) - 
Proportion impaired (%) 10/53 (18.87)  
Rey copy (max=12) 9.48 (3.56) - 
Proportion impaired (%) 28/50 (56)  
Boston Naming Test (max=30) 20.5 (8.08)  
Proportion impaired (%) 16/44 (36.36) 
Abbreviation: MMSE=Mini-Mental State Examination 
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Table 2. Results of a group comparison analysis showing regions of reduced 
gray matter (GM) density in frontotemporal lobar degeneration (FTLD) patients 
relative to healthy controls (Analysis 1), and results of regression analyses in 
patients (Analysis 2a) and controls (Analysis 2b) showing a positive relationship 
between GM density and cognitive reserve (CR) in regions from Analysis 1. 
 
Neuroanatomic region (BA) L/R MNI p Voxels 
Coordinates value 
Analysis 1. Reduced GM density in FTLD relative to x y z 
controls: 
Occipital Temporal Cortex (37) R 36 0 -46 0.001 8250 
Inferior Temporal Cortex (20) L -34 0 -46 0.001 6966 
Orbital Frontal Cortex (11/25) L -8 24 -26 0.001 838 
Thalamus/Hypothalamus R 2 -10 -14 0.001 586 
Hippocampus R 32 -10 -24 0.001 180 
Parietal Cortex (40) L -62 -28 20 0.001 142 
Hippocampus L -22 -10 -26 0.001 119 
Superior Temporal Cortex (22) R 66 -30 18 0.001 75 
Parietal Cortex (40) R 62 -28 40 0.001 72 
Angular Gyrus (39) R 64 -44 26 0.001 54 
Analysis 2a. Higher GM density associated with higher CR in FTLD: 
Rostral Frontal Cortex (10) R 32 50 20 0.001 133 
Orbital Frontal Cortex (47) R 50 28 -4 0.003 123 
Inferior Frontal Gyrus (44/45) R 52 12 22 0.01 64 
Dorsolateral Prefrontal Cortex (8/9) R 44 6 40 0.005 59 
Analysis 2b. Higher GM density associated with higher CR in controls: 
Inferior Frontal Gyrus (44/45) L -42 18 6 0.003 60 




Table 3. In FTLD patients, mean GM density in regions positively associated with 
CR from Analysis 2a are also positively correlated with performance on letter 
fluency, but not on MMSE, forward digit span, Rey copy, or the Boston Naming 








































































Note. Bonferroni corrected *p<0.05; **p<0.001 
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Table 4. Results of two whole-brain regression analyses examining CR index 
relative to whole-brain GM density in FTLD patients and in controls. We report 
clusters that survive a p<0.05 (uncorrected) threshold and cluster extent 
threshold of >50 adjacent voxels relative to 10,000 random permutations. 
Regression analysis in patients included disease duration and age at MRI as 
nuisance covariates, and regression analysis in healthy controls included age at 
MRI as a nuisance covariate. 
 
Neuroanatomic region (BA) L MNI Coordinates p Voxels 
/ value 
R 
Higher GM density associated with higher CR in FTLD: x y z 
Dorsolateral Prefrontal Cortex (9) R 34 36 38 0.001 479 
Rostral Frontal Cortex (10) R 36 42 10 0.001 455 
Visual Association Cortex (18) L -30 -90 -10 0.001 339 
Fusiform Gyrus (37) R 60 -40 -22 0.001 296 
Visual Association Cortex (19) R 36 -88 -14 0.001 234 
Orbital Frontal Cortex (47) R 50 28 -4 0.003 195 
Premotor Cortex (6) L -26 0 64 0.001 115 
Premotor Cortex (6) R 58 2 44 0.003 110 
Supramarginal Gyrus (40) L -54 -40 40 0.001 106 
Premotor Cortex (6) L -10 -106 2 0.001 90 
Premotor Cortex (6) R 28 6 56 0.001 64 
Supramarginal Gyrus (40) R 56 -40 36 0.004 61 
Middle Temporal Gyrus (21) L -62 -24 -16 0.002 60 
Cerebellum L -34 -86 26 0.002 59 
Rostral Frontal Cortex (10) L -44 46 22 0.004 59 
Middle Temporal Gyrus (21) L -64 -38 -8 0.003 54 
Supramarginal Gyrus (40) R 50 -48 44 0.004 52 
Higher GM density associated with higher CR in 
controls: 
Posterior Cingulate Cortex (31) L -8 -38 -44 0.001 392 
Anterior Temporal Cortex (38) R 46 22 -30 0.001 183 
Inferior Frontal Gyrus (45) L -56 22 12 0.001 117 
Visual Association Cortex (18) L -4 -96 -14 0.001 107 
Visual Association Cortex (18) L -4 -96 14 0.004 74 
Primary Visual Cortex (17) R 8 -82 8 0.005 61 
Orbital Frontal Cortex (11) R 12 34 -26 0.003 56 
Primary Sensory Cortex (1) R 64 -18 34 0.001 52 




Table 5. Results of two regression analyses showing a positive relationship 
between GM density and education and occupation in regions from Analysis 1 in 
FTLD patients. We report clusters that survive a p<0.05 (uncorrected) threshold 
and cluster extent threshold of >50 adjacent voxels relative to 10,000 random 
permutations. Regression analysis in patients included disease duration and age 
at MRI as nuisance covariates. 
 
Neuroanatomic region (BA) L/R MNI p Voxels 
Coordinates value 
Higher GM density associated with higher education in x y z 
FTLD: 
Inferior Frontal Gyrus (44)  R 58 10 22 0.002 316 
Rostral Frontal Cortex (10)  R 42 44 10 0.001 194 
Orbital Frontal Cortex (47)  R 50 34 -6 0.002 146 
Caudate (48)  R 12 8 10 0.005 119 
Premotor Cortex (6)  L -50 0 50 0.006 66 
Higher GM density associated with higher 
occupation in FTLD: 
Orbital Frontal Cortex (47)  R 44 30 -14 0.001 1310 
Orbital Frontal Cortex (47)  L -40 30 -16 0.001 508 
Orbital Frontal Cortex (11)  R 8 36 -24 0.001 473 
Middle Temporal Gyrus (21)  R 58 -8 -16 0.002 448 
Inferior Frontal Gyrus (44)  R 58 10 20 0.001 436 
Rostral Frontal Cortex (10)  L -36 56 6 0.002 262 
Anterior Temporal Cortex (38)  R 30 8 -40 0.004 135 
Anterior Temporal Cortex (38)  L -32 18 -36 0.007 87 
Inferior Frontal Gyrus (44)  L -62 -18 -22 0.003 74 
Dorsolateral Prefrontal Cortex (46) L -40 30 22 0.005 65 
Orbital Frontal Cortex (11)  L -8 40 -24 0.007 52 




Figure 1. (Analysis 1) Results of a nonparametric t-test showing regions of 
reduced grey matter (GM) density in Frontotemporal Lobar Degeneration patients 
(N=55) relative to demographically-comparable controls (N=90). (Analysis 2a) 
Results of a regression analysis in FTLD patients (N=55) restricted to regions of 
reduced GM density from Analysis 1 (white regions) demonstrating that GM 
density in the right dorsolateral prefrontal cortex, rostral frontal cortex, orbital 
frontal cortex, and inferior frontal gyrus is positively associated with Cognitive 
Reserve (CR) index. (Analysis 2b) Results of a regression analysis in healthy 
controls (N=90) demonstrating that GM density in the left inferior frontal gyrus is 
positively associated with CR index. Color bar represents 1—p-value with yellow 




Figure 2. Mean GM density in the right rostral frontal cortex, inferior frontal 
gyrus, orbital frontal cortex, and dorsolateral prefrontal cortex positively 
associated with CR from Analysis 2a are also positively associated with 




























































































































































Figure 3. Results of a regression analysis in FTLD patients (N=55) restricted to 
regions of reduced GM density from Analysis 1 (pictured in white) demonstrating 
that when considered separately, educational category (A) and occupational 
category (B) each are significantly positively associated with right frontal cortex 
GM density, largely converging with our results using Cognitive Reserve (CR) 
index as a combined metric of educational and occupational category (Post hoc 








UNC13A polymorphism contributes to frontotemporal disease in sporadic 
amyotrophic lateral sclerosis 
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The majority (90-95%) of amyotrophic lateral sclerosis (ALS) is sporadic, and 
 
~50% of patients develop symptoms of FTD associated with shorter survival. The 
genetic polymorphism rs12608932 in UNC13A confers increased risk of sporadic 
ALS and sporadic frontotemporal degeneration (FTD), and modifies survival in 
ALS. Here, we evaluate whether rs12608932 is also associated with 
frontotemporal disease in sporadic ALS. We identified reduced cortical thickness 
in sporadic ALS with T1-MRI (N=109) relative to controls (N=113), and observed 
that minor allele (C) carriers exhibited greater reduction of cortical thickness in 
dorsal prefrontal, ventromedial prefrontal, anterior temporal, and middle temporal 
cortices and worse performance on a frontal-lobe mediated cognitive test 
(reverse digit span). Association between rs12608932 and cortical thickness was 
not observed in an independent control cohort from the Alzheimer’s Disease 
Neuroimaging Initiative (N=84). In sporadic ALS with autopsy data (N=102), 
minor allele homozygotes exhibited greater burden of pTDP-43 pathology in the 
middle frontal, middle temporal, and motor cortices. Our findings demonstrate 
converging  evidence  that  rs12608932  may  modify  frontotemporal  disease  in 
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sporadic ALS, and suggest that rs12608932 may function as a prognostic 





Amyotrophic lateral sclerosis (ALS) is a multi-system disorder primarily 
characterized by progressive degeneration of the upper and lower motor neurons 
(UMN, LMN) and affected individuals typically survive 2-5 years from symptom 
onset (Chiò et al. 2009). An estimated ~50% of individuals with ALS also develop 
impairments in at least one cognitive domain including executive function, social 
behavior, or language indicative of extramotor neurodegeneration in the frontal 
and temporal lobes, and about 10% of these individuals develop multi-domain 
impairments consistent with frank frontotemporal degeneration (FTD) (Montuschi 
et al. 2015; Ringholz et al. 2005). While ALS and FTD commonly feature tar 
DNA-binding protein-43kda (TDP-43) pathology (Neumann et al. 2006) and can 
both be caused by pathogenic C9ORF72 repeat expansions (Renton et al. 2011; 
DeJesus-Hernandez et al. 2011), the mechanisms influencing the risk of 
progression from ALS to develop cognitive impairment and FTD have been 
under-evaluated. The presence of FTD is consistently associated with shorter 
survival in ALS patients (Govaarts et al. 2016; Elamin, Phukan, Bede, Jordan, 
Byrne, Pender, and Hardiman 2011b), and therefore it is critical to identify risk 
factors for frontotemporal disease in ALS. 
The vast majority of ALS is considered “sporadic”, with only a small 
proportion of approximately 5-10% of ALS patients featuring a familial history or 
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autosomal dominant source of disease (e.g. C9ORF72 expansions) (Taylor, 
Brown, and Cleveland 2016). Therefore, it is important to consider sources of 
common genetic variation that may influence risk of disease – including FTD - in 
ALS. Case-control genome-wide association studies (GWAS) have identified 
several single nucleotide polymorphisms (SNPs) associated with increased odds 
of having ALS (van Rheenen et al. 2016) or FTD (Van Deerlin et al. 2010). More 
recently, two loci, including rs3849942 in the C9ORF72 gene and rs4239633 in 
the UNC13A gene demonstrate shared genetic overlap between ALS and FTD 
(Karch et al. 2018). The observed rs3849942 SNP is a marker of the C9ORF72 
expansion haplotype (Jones et al. 2013) with no additional genetic influence 
reported. However, loci in UNC13A including rs12608932, that is in high linkage 
disequilibrium (LD) with rs4239633 (D’=0.83), are associated with increased risk 
of sporadic ALS (van Es et al. 2009) and sporadic FTD with underlying TDP-43 
pathology (Diekstra et al. 2014). Clinical studies have further suggested that the 
minor allele (C) of rs12608932 (MAF=0.43) is associated with shorter survival in 
sporadic ALS, which has been demonstrated in multiple populations and under 
both additive and recessive minor allele models (Diekstra et al. 2012; Vidal- 
Taboada et al. 2015; Chiò et al. 2013). 
In this report we perform a multimodal evaluation of rs12608932 to further 
investigate evidence for shared risk between ALS and FTD. Specifically, we test 
the hypothesis that the disease-associated allele (C) in rs12608932 is associated 
with frontotemporal cortical disease in sporadic ALS, including reduced cortical 







We evaluated 190 sporadic ALS cases distributed across a neuroimaging, 





We retrospectively evaluated 109 sporadic ALS patients recruited for research 
between 2004 and 2017 from the Penn Comprehensive ALS Clinic and Penn 
Frontotemporal Degeneration Center at the University of Pennsylvania Perelman 
School of Medicine. All patients were diagnosed with ALS by a board-certified 
neurologist (L.E., L.M., M.G., D.I) using the revised El Escorial criteria (Brooks et 
al. 2000), including possible, probable, and definite ALS. All patients were also 
assessed for frontotemporal dysfunction using established criteria (Strong et al. 
2009) and those patients enrolled in research prior to 2009 were retrospectively 
evaluated through a chart review; in total 26 patients were diagnosed with ALS- 
FTD and 11 patients were diagnosed with ALS-cognitive impairment (ALSci). 
To identify regions of significant cortical thinning in ALS, we recruited 113 
demographically-comparable healthy controls who self-reported a negative 
history for neurologic or psychiatric disease and scored >27 on the MMSE. There 
were no statistically significant differences in age, education, or sex between 
controls and ALS (all p values > .05). We assessed participant race and ethnicity 
via self-report. While population diversity is known to influence allele frequency 
across individuals, rs12608932 has a relatively equal minor allele frequency 
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across populations (e.g., European 0.35, Africans 0.33, American 0.30) and post- 
hoc analyses limited to the majority race and ethnicity of our patient population 
(e.g. white non-Latino) remain significant or approach significance. Demographic 
features of ALS and controls are summarized in Table 6. 
All participants participated in an informed consent procedure approved by 





We evaluated neuropathological data from 102 sporadic ALS autopsy cases who 
were diagnosed by a board-certified neuropathologist (JQT, EBL) with ALS due 
to TDP-43 pathology using immunohistochemistry (Lippa et al. 2009; Neumann 
et al. 2006) and published criteria (Mackenzie et al. 2011). This cohort included 
21 patients from the ALS neuroimaging cohort. Autopsy cases were identified 
from the Integrated Neurodegenerative Disease Database (Toledo et al. 2014) 
after excluding cases with a family history of neurodegenerative disease or a 
known genetic mutation associated with ALS (see Genetic Screening). Within  
this autopsy cohort we rated the extent of phosphorylated TDP-43 (pTDP-43) 
intraneuronal inclusions (dots, wisps, skeins) for each sampled region on a semi- 
quantitative ordinal scale: 0 = none/rare, 1 = mild, 2 = moderate, 3 = 
severe/numerous (Toledo et al. 2014). All neuropathological ratings were 
performed by an expert neuropathologist (JQT, EBL) blinded to genotype. 





Alzheimer’s disease neuroimaging initiative (ADNI) cohort. 
 
To evaluate the disease specificity of any observed neuroanatomic and genetic 
associations we additionally performed cortical thickness analyses in 84 amyloid- 
negative (florbetapir SUVR <1.11) (Landau et al. 2012), cognitively-normal 
healthy controls from the publicly-available Alzheimer’s Disease Neuroimaging 





DNA was extracted from peripheral blood or frozen brain tissue following the 
manufacturer’s protocols (Flexigene (Qiagen) or QuickGene DNA whole blood kit 
(Autogen) for blood, and QIAsymphony DNA Mini Kit (Qiagen) for brain tissue). 
All patients were screened for C9ORF72 hexanucleotide repeat expansions  
using a modified repeat-primed polymerase-chain reaction (PCR) as previously 
described (Suh et al. 2015), and we excluded any patient with >=30 
hexanucleotide repeats. Of the remaining individuals, we evaluated  family  
history using a three-generation pedigree history as previously reported (Wood et 
al. 2013). For cases with a family history of the same disease we sequenced 45 
genes previously associated with neurodegenerative disease (Toledo et al. 
2014), including four genes known to be associated with ALS (e.g. SOD1 (D. R. 
Rosen 1993), TARDBP (Kabashi et al. 2008), FUS (Kwiatkowski et al. 2009; 
Vance et al. 2009), and VCP (J. O. Johnson et al. 2010)). Sequencing was 
performed using a custom-targeted next-generation sequencing panel (MiND- 
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Seq) (Toledo et al. 2014), and analyzed using Mutation Surveyor software (Soft 






All neuroimaging and neuropathology cases were genotyped using peripheral or 
brain DNA, extracted as above, for rs12608932 using a custom-designed Pan 
Neurodegenerative Disease-oriented Risk Allele (PANDoRA) panel designed to 
genotype 92 common and risk allele variants identified in association and other 
studies as modifying risk of disease or a phenotype for several 
neurodegenerative diseases, including ALS as well as FTD, Parkinson’s disease, 
and Alzheimer’s disease (Toledo et al. 2014). While our analyses focus on a 
single genotype, rs12608932, this approach provides a cost-effective manner to 
genotyping that can be used for future comparative studies as previously 
reported by our center (McMillan et al. 2018; McMillan et al. 2014). Briefly, the 92 
SNP Type assays were designed by D3 Assay Design tool (Fluidigm). Allele- 
specific PCR was performed using the 96.96 Dynamic Array integrated fluidic 
circuits (Fluidigm) and genotyping was carried out using the BioMark HD system 
(Fluidigm) according to the manufacturer’s protocol. The genotype call data was 
collected and analyzed using BioMark Genotyping Analysis software. 
All ADNI healthy control data was genotyped using the Illumina 660K, as 
previously described (Del-Aguila et al. 2018). As part of routine quality control 
steps, single-nucleotide polymorphisms (SNPs) with minor allele frequency < 1%, 
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call rates < 98%, Hardy–Weinberg equilibrium p-values >10-6 and individuals with 
 
> 2% missing genotypes were removed before imputation. The dataset was 
imputed, separately, using SHAPEIT/IMPUTE2 with the 1000 Genomes Project 
as the reference panel. All genotypes with dosage levels <0.9 for all three 
possible genotypes or with information scores <0.3 were excluded. Variants out 
of Hardy Weinberg Equilibrium (HWE) (p<1x10-6) or with a genotyping rate below 
95% were also omitted from the analyses. Population structure was inferred by 
principal component (PC) analysis using PLINK v.1.9. PLINK v1.9 was also used 





Detailed clinical evaluations were available for a subset of 88 (79%) sporadic 
ALS patients in the neuroimaging cohort. These patients were clinically  
assessed within approximately two months of neuroimaging acquisition date (M 
=1.62, SD = 2.63) for motor function using the Revised ALS Functional Rating 
Scale (ALSFRS-R) (Cedarbaum, Stambler, Malta, Fuller, Hilt, Thurmond, and 
Nakanishi 1999a) and cognitive function using the Forward and Reverse Digit 
Span, the Visual-Verbal Test (VVT), letter fluency, and the Mini-Mental State 
Exam (MMSE). Forward digit span, a measure of auditory-verbal short-term 
memory, and reverse digit span, a measure of auditory-verbal working memory, 
were assessed in an untimed manner with repetition of increasingly longer 
sequences until the patient erred; the maximum number of digits on a correct trial 
was recorded (Wechsler 1945). Our group has previously demonstrated that the 
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VVT is a brief, untimed measure of cognitive flexibility with minimal motor 
demands appropriate for use in an ALS patient population (Evans et al. 2015). 
Participants first identify a feature shared by three of four simple geometric 
designs, and are next challenged to identify a different feature shared by another 
combination of three of the four same geometric designs; a discrepancy between 
the number correct on the first and second identifications of 10 trials is 
considered a sign of reduced mental flexibility. Letter fluency is a measure of 
executive control and verbal ability (Abrahams et al. 2000), and was assessed by 
the number of unique words beginning with “F” a patient was able to generate in 
one minute (excluding proper nouns and numbers); patients did not complete 
letter fluency if bulbar upper or lower motor symptoms were present upon exam. 
The MMSE is a 30-point questionnaire that evaluates global dementia severity 
(Crum, Anthony, Bassett, and Folstein 1993b); we calculated the percentage 
correct on MMSE as some patients were not able to complete the entire test due 
to motor disability. 
In addition to reporting raw patient performance on neuropsychological 
assessments, we report the percent of patients impaired on each task relative to 
published normative data of healthy controls matched to the mean age and mean 
education of our patients where available (Tombaugh, Kozak, and Rees 1999; 
Weintraub et al. 2009). We report patient performance on the Visual Verbal Test 
relative to normative data based on healthy controls recruited by the Penn 
Frontotemporal Degeneration Center who were matched to the mean age and 
mean education of our patients (N=31 (17 Female); Age, years: M=60.58, 
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SD=12.80; Education, years: M=15.29, SD=2.52). We defined patient impairment 
on each task as performance at or greater than 1.96 standard deviations, 
equivalent to p<0.05, below normative data from healthy controls. 
 
 
Neuroimaging acquisition & processing. 
 
High-resolution T1-weighted MPRAGE structural scans were acquired for 
neuroimaging participants using a 3T Siemens Tim Trio scanner with an 8- 
channel head coil, with T=1620ms, T=3.09ms, flip angle=15°, 192x256 matrix, 
and 1mm3 voxels. T1-weighted MRI images were then preprocessed using ANTs 
Cortical Thickness software (Tustison et al. 2014). Each individual dataset was 
deformed into a standard local template space in a canonical stereotactic 
coordinate system. Advanced Normalization Tools (ANTs) provides a highly 
accurate registration routine using symmetric and topology-preserving 
diffeomorphic deformations to minimize bias toward the reference space and to 
capture the deformation necessary to aggregate images in a common space. 
Then, we used N4 bias correction to minimize heterogeneity (Tustison et al. 
2010) and the ANTs Atropos tool to segment images into six tissue classes 
(cortex, white matter, CSF, subcortical grey structures, brainstem, and 
cerebellum) using template-based priors and to generate probability maps of 
each tissue. Voxel-wise cortical thickness was measured in millimeters (mm) 
from the pial surface and then transformed into Montreal Neurological Institute 
(MNI) space, smoothed using a 2 sigma full-width half-maximum Gaussian 







We used randomise software from FSL to perform nonparametric, permutation- 
based statistical analyses of cortical thickness images from our ALS and control 
neuroimaging cohorts and the ADNI control cohort. Permutation-based statistical 
testing is robust to concerns regarding multiple comparisons since, rather than a 
traditional assessment of two sample distributions, this method assesses a true 
assignment of factors (e.g., genotype) to cortical thickness relative to many (e.g., 
10,000) random assignments (Winkler et al. 2014). 
First, we identified regions of reduced cortical thickness in ALS relative to 
healthy controls, constraining analysis using an explicit mask restricted to high 
probability cortex (>.4). We report clusters that survive p<.005 threshold-free 
cluster enhancement (TFCE) (Smith and Nichols 2009) corrected for family-wise 
error (FWE) relative to 10,000 random permutations. 
Next, we evaluated whether rs12608932 genotype relates to magnitude of 
reduced cortical thickness in ALS, covarying for disease duration, age, and sex in 
an effort to control for factors associated with reduced cortical thickness but not 
specifically associated with SNP genotype. We restricted this analysis to a mask 
defined by regions of reduced cortical thickness in ALS relative to controls so that 
we could focus our interpretation in the context of cortical degeneration affected 
by ALS. We report clusters that survive p<.01 (uncorrected) threshold  and 
cluster extent threshold of >20 adjacent voxels relative to 10,000 random 
permutations; we employ an uncorrected threshold to minimize the chance of 
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Type II error (not observing a true result). 
 
We performed comparable analyses to evaluate SNP genotype relative to 
cortical thickness in the ADNI control cohort and adopted the same statistical 





All additional statistical analyses were performed using R. For assessment of 
ordinal neuropathology data we performed ordinal logistic regression using the 
MASS package in R to investigate whether burden of TDP-43 pathology differed 
according to genotype at rs12608932, covarying for age, sex, and disease 
duration at death. For clinical comparisons, we used multiple linear regression to 
evaluate the association between genotype at rs12608932 and performance on 
forward and reverse digit span, the MMSE, the VVT, and letter fluency; we 
included age, sex, disease duration, ALSFRS-R total score, and cognitive 





Reduced cortical thickness in ALS associated with the rs12608932 minor allele. 
A group comparison of ALS patients relative to healthy controls revealed reduced 
cortical thickness in the bilateral frontal and temporal lobes, consistent with the 
pattern of cortical degeneration associated with ALS-FTD spectrum disorders 
(Table 8, Figure 4). 
To evaluate disease-specific genotype and neuroanatomic associations 
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we restricted our subsequent analyses to regions of reduced cortical thickness 
observed in ALS. Evaluation of rs12608932 under a minor allele additive model 
revealed reduced cortical thickness associated with the minor allele (C) in the 
right anterior temporal lobe, bilateral ventromedial prefrontal cortex, left middle 
temporal gyrus, and left dorsal prefrontal cortex (Table 8, Figure 4A). Evaluation 
of rs12608932 under a minor allele recessive model revealed reduced cortical 
thickness associated with the minor allele (C) in regions including the dorsal and 
dorsolateral prefrontal, ventromedial prefrontal, anterior temporal, and middle 
temporal cortices (Table 8, Figure 4B). 
Investigation of the inverse association between rs12608932 genotype 
(i.e. number of major non-risk allele “A”) and cortical thickness yielded no 
statistically significant findings for either additive or recessive models (not 
shown), suggesting that the rs12608932 minor allele C is specifically associated 
with reduced cortical thickness in these regions. 
To examine the disease specificity of the relationship between 
rs12608932 genotype and reduced cortical thickness in ALS, we performed 
comparable analyses in the ADNI control cohort restricted to the same regions of 
reduced cortical thickness observed in ALS. We observed no relationship 
between cortical thickness and genotype at rs12608932 under minor allele 
additive or recessive models (not shown). 
 
 
Working memory performance associated with rs12608932. 
 
Given the observed association between rs12608932 and frontal and temporal 
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cortices, we evaluated each clinical assessment to investigate potential clinical 
consequences of the observed neuroanatomic and genetic associations. 
We first investigated whether ALSFRS-R relates to rs12608932 genotype. 
Under a minor allele additive model, minor allele heterozygotes (AC) (=3.41, 
p=.04) but not minor allele homozygotes at rs12608932 (CC) (=1.97, p=.35) 
demonstrated higher ALSFRS-R total score compared to major allele 
homozygotes (AA); disease duration (=-.037, p=.1), age (=.059, p=.38), sex 
(=1.53, p=.33), and cognitive diagnosis (ALSci: =-2.34, p=.37; ALS-FTD: =- 
0.88, p=.62) were not found to significantly affect ALSFRS-R Total in this model. 
However, under a minor allele recessive model, we did not observe a significant 
difference in ALSFRS-R Total score between minor allele heterozygotes (AC) 
and minor allele homozygotes (CC) at rs12608932 (=0.34, p=.87) compared to 
major allele homozygotes (AA). To account for the observed difference in 
ALSFRS-R under a minor allele additive model, we covaried for ALSFRS-R Total 
score in all subsequent regressions. 
Under a minor allele additive model, we observed a trend whereby minor 
allele homozygotes at rs12608932 (CC) (=-.81, p=.086) performed worse than 
major allele homozygotes (AA) on reverse digit span after accounting for 
cognitive diagnosis (ALSci: =-1.73, p=.0014; ALS-FTD: =-2.09, p<.00001); 
heterozygous genotype (AC) (=.32, p=.38), disease duration (=-.0022, p=.64), 
ALSFRS-R total score (=-.012, p=.60), and age (=-.0021, p=.89) did not relate 
to reverse digit span performance in this model. 
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Under a minor allele recessive model, minor allele homozygotes at rs12608932 
(CC) (=-0.96, p=.029) performed significantly worse than major allele 
homozygotes (AA) and heterozygotes (AC) on reverse digit span  after 
accounting for cognitive diagnosis (ALSci: =-1.69, p=.0017; ALS-FTD: =-2.08, 
p<.00001); disease duration (=-.0018, p=.69), ALSFRS-R total score (=-.0013, 
p=.95), age (=-.0013, p=.76), and sex (=.55, p=.11), did not significantly relate 
to reverse digit span performance in this model. 
Performance on other neuropsychological tests was not found to associate with 
rs12608932  genotype,  including  forward  digit  span  (CC:  =-.03,  p=.93;  CA: 
=.40, p=.20), letter fluency (CC: =.26, p=.85; CA: =1.61 p=.15), MMSE (CC: 
 
=.036, p=.28; CA: =.006, p=.82), and the VVT (CC: =-.22, p=.67; CA: =-.40, 
 
p=.32). We observed similar results under minor allele recessive models: forward 
digit span (CC: =-.22, p=.57),  letter fluency (CC: =-.39, p=.76), MMSE (CC: 
=.034, p=.26), and the VVT (CC: =.12, p=.80). 
 
 
pTDP-43 pathologic burden associated with rs12608932. 
 
To evaluate converging evidence for our observed genetic and neuroanatomic 
associations, we assessed ordinal neuropathologist ratings of pTDP-43 
pathologic burden in the middle frontal, temporal, and motor cortices, which were 
associated with rs12608932 in the above neuroimaging analyses (Figure 5). 
Minor allele homozygotes (CC) were 8.26 times (95% CI: 2.01, 38.64; p = 
 
.0043) more likely and heterozygotes (AC) were 5.53 times (95% CI: 1.78, 21.21; 
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p = .0057) more likely to have higher TDP-43 burden in the middle frontal cortex 
relative to major allele homozygotes (AA). Minor allele homozygotes (CC) were 
4.40 times (95% CI: 1.25, 16.23; p = .022) more likely to have higher TDP-43 
burden in the temporal cortex and – reaching marginal significance - 3.04 times 
(95% CI: 0.98, 9.72; p = .056) more likely to have higher TDP-43 burden in the 
motor cortex relative to major allele homozygotes (AA); minor allele 
heterozygotes (AC) were not more likely to have higher TDP-43 burden relative 
to major allele homozygotes in either region (both p values > .1). 
We repeated our analysis of TDP-43 pathologic burden in the middle 
frontal, temporal, and motor cortices in our autopsy cohort after excluding 21 
individuals in the autopsy cohort who were also in the neuroimaging cohort. 
Similar to our findings in the entire autopsy cohort, minor allele homozygotes 
(CC) were 28.35 times (95% CI: 4.72, 249.31; p = .00064) more likely and 
heterozygotes (AC) were 11.49 times (95% CI: 2.78, 78.76; p = .0027) more 
likely to have higher TDP-43 burden in the middle frontal cortex relative to major 
allele homozygotes (AA). Minor allele homozygotes (CC) were 11.60 times (95% 
CI: 2.23, 72.49; p = .005) more likely to have higher TDP-43 burden in the 
temporal cortex relative to major allele homozygotes (AA); minor allele 
heterozygotes (AC) were not more likely to have higher TDP-43 burden relative 
to major allele homozygotes (p > .9). We did not observe any statistically 
significant differences in TDP-43 pathologic burden in the motor cortex relative to 





In this study, we evaluated whether rs12608932 genotype in UNC13A was 
associated with frontotemporal disease in sporadic ALS using a novel multimodal 
approach integrating genetic, neuroimaging, clinical, and neuropathology data. 
Our results indicate that sporadic ALS patients who are carriers of the 
rs12608932 minor allele (C) show reduced cortical thickness in regions including 
the dorsal and ventromedial prefrontal cortex, anterior and middle temporal 
cortex, and premotor cortex, and that minor allele homozygotes (CC) 
demonstrate worse performance on reverse digit span, a frontal-lobe mediated 
cognitive test. We did not observe a relationship between rs12608932 genotype 
and cortical thickness in the amyloid-negative ADNI healthy control cohort, 
suggesting that the association between rs12608932 and reduced cortical 
thickness is specific to ALS. Furthermore, in our sporadic ALS autopsy cohort,  
we demonstrate that carriers of the rs12608932 minor allele have increased odds 
of pTDP-43 pathologic burden in the middle frontal cortex, middle temporal 
cortex, and motor cortex, consistent with our neuroimaging findings. To our 
knowledge, our study provides novel evidence that the minor allele of 
rs12608932 in UNC13A is associated with in vivo frontotemporal cortical atrophy, 
impaired cognitive performance, and greater burden of pTDP-43 pathological 
inclusions in sporadic ALS. 
rs12608932 was first identified through a two-stage GWAS as a 
susceptibility locus for sporadic ALS with a combined P = 2.53 x 10(-14) (van Es 
et al. 2009). rs12608932 maps to a haplotype block within the boundaries of 
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gene UNC13A, which regulates presynaptic vesicle priming and glutamate 
release at neuromuscular synapses, and mice lacking the UNC13A homolog 
have arrested synaptic vesicle maturation and disrupted glutamatergic 
transmission (Augustin et al. 1999). Subsequent population-based study 
indicated the minor allele (C) at rs12608932 as a risk factor for shorter survival in 
sporadic ALS under both additive and recessive models (Diekstra et al. 2012; 
Chiò et al. 2013; Vidal-Taboada et al. 2015), and as a modifier of physical 
symptom progression on the ALSFRS-R (Vidal-Taboada et al. 2015). In addition 
to risk and progression of sporadic ALS, rs12608932 was also identified to serve 
as a risk locus for sporadic FTLD-TDP (Diekstra et al. 2014), suggesting 
rs12608932 as a potential link between ALS and FTLD-TDP. More recently, an 
additional SNP in UNC13A in high LD with rs12608932 (rs4239633; D’=0.83) 
was identified as demonstrating selective genetic overlap between ALS and FTD 
in GWAS meta-analysis (Karch et al. 2018). 
Our findings corroborate rs12608932 as a genetic link between ALS and 
FTD with TDP-43 pathology, and specifically demonstrate that the minor allele is 
associated with reduced cortical thickness, worse working memory performance, 
and greater burden of TDP-43 pathology in the frontal and temporal lobes. 
Importantly, we use continuous disease traits from multiple modalities (i.e. 
structural imaging, cognitive testing, neuropathology data) to present converging 
evidence that rs12608932 confers increased risk of frontotemporal disease in 
sporadic ALS and relates to patient cognitive performance. This approach offers 
an advance over discovery GWAS that compare only categorical clinical 
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designations (e.g. ALS vs. healthy controls), and allows detailed phenotypic 
characterization associated with rs12608932 genotype. 
Furthermore, the observed relationship between rs12608932 and both 
frontotemporal cortical thinning and burden of TDP-43 pathology are consistent 
with the disease anatomy of ALS-FTD spectrum disorders. Structural MRI 
studies have previously demonstrated progressive frontotemporal gray matter 
degeneration over disease course (Menke et al. 2014; Verstraete et al. 2014; 
Kwan et al. 2013; Verstraete et al. 2012; Keil et al. 2012; Senda et al. 2011; 
Müller et al. 2016), and that degree of frontotemporal cortical thinning relates to 
cognitive-behavioral phenotype (Agosta et al. 2016; Schuster et al. 2014). 
Additionally, staging of neuropathological burden suggests stereotyped 
propagation of TDP-43 from motor regions (brainstem, spinal cord) to frontal and 
temporal neocortex over the course of disease (Brettschneider et al. 2013; Braak 
et al. 2013). Our finding of greater TDP-43 pathologic burden associated with the 
rs12608932 in frontal and temporal neocortex may thus be interpreted to reflect 
more progressive disease propagation in sporadic ALS patients who are minor 
allele carriers. This finding could also be related to TDP-43 pathologic subtype 
(Mackenzie et al. 2011), and future work is necessary to 1) evaluate the influence 
of TDP-43 pathologic subtype on the anatomic distribution and phenotypic 
presentation (e.g. comorbid symptoms of frontotemporal disease) of disease, and 
2) investigate how rs12608932 genotype relates to TDP-43 pathologic subtype. 
 
With this in mind, rs12608932 genotype may potentially be used prognostically to 
evaluate  risk  of  frontotemporal  cortical  disease  in  ALS,  which  has  been 
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previously associated with reduced survival (Govaarts et al. 2016; Elamin, 
Phukan, Bede, Jordan, Byrne, Pender, and Hardiman 2011b). 
The observed relationships between rs12608932, reduced cortical 
thickness in the dorsal and ventromedial prefrontal cortices, and worse 
performance on reverse digit span are congruent with the neuroanatomy of 
working memory. Indeed, functional activation of the dorsal and ventromedial 
prefrontal cortices relates to memory load function and information retrieval on 
tasks of working memory, respectively (Rypma and D’Esposito 1999). 
We also observed a relationship between rs12608932 and reduced 
cortical thickness in the right orbital frontal cortex, right anterior temporal lobe, 
and left middle temporal gyrus. Our group has previously shown that reduced 
cortical thickness in the orbital frontal cortex is associated with behavioral 
disinhibition and apathy in patients with FTD (Massimo et al. 2009), while others 
have shown that cortical thinning in the right anterior temporal lobe and left 
middle temporal gyrus are associated with impaired semantic knowledge and 
theory of mind in patients with FTD (Irish, Hodges, and Piguet 2014; Rohrer et al. 
2009). Impairments in behavior and language are common to both ALS and FTD 
(Beeldman et al. 2018), and prospective studies are necessary to evaluate 
potential rs12608932 associations relative to language and behavioral function 
using more comprehensive neuropsychological batteries like the Edinburgh 
Cognitive Assessment Scale (ECAS) (Abrahams et al. 2014), which were not 
available in this retrospective study. 
Our findings add to an increasing body of evidence in support of a 
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clinicopathologic continuum between ALS and FTD with underlying TDP-43 
pathology, and specifically suggest that genetic polymorphisms may relate to the 
phenotypic presentation of frontotemporal disease in sporadic ALS. This is 
consistent with prior work from our group demonstrating that TDP-43 pathology- 
associated SNPs relate to selective neuroanatomic distribution of cortical atrophy 
and white matter degeneration in patients with sporadic forms of FTD (McMillan 
et al. 2014), modify disease onset and survival in FTD with C9ORF72 repeat 
expansions (“TMEM106B is a Genetic Modifier of Frontotemporal Lobar 
Degeneration with C9ORF72 Hexanucleotide Repeat Expansions (I5-1.008),” 
2014) (Gallagher et al. 2014), and confer risk for impaired executive function in 
ALS (Vass et al. 2011). 
The identification of genetic polymorphisms associated with disease 
phenotypes holds important implications for both basic science research and 
translational application. Our observed association between rs12608932 and 
frontotemporal disease in sporadic ALS motivates further investigation into 
potential mechanisms of disease vulnerability associated with genetic 
polymorphisms. While the function of gene UNC13A has previously been 
characterized (Augustin et al. 1999), future work is necessary to determine the 
extent to which rs12608932 genotype provides an actual disease modifier or is 
an association related to matching downstream transcription sites or other long- 
range interactions (Haiquan Li et al. 2016). In regards to translational application, 
our findings may contribute to patient stratification for clinical trials. Prior research 
has demonstrated baseline differences in patients stratified for SNP genotype 
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and indicate a contribution of genetic polymorphisms in dose-response to 
treatment (D. Wang et al. 2011), leading to the incorporation of genetic 
polymorphisms in the design and analysis of clinical trials (Zhang et al. 2017). 
Several caveats should be considered in the present study. Our data were 
limited according to strict inclusion criteria to investigate the clinical, pathologic, 
and regional anatomical differences in sporadic ALS patients relative to 
rs12608932 genotype. While we establish multiple sources of converging 
evidence for rs12608932 genotype relating to frontal disease, replication of the 
present findings in a large independent cohort using a prospective design is 
necessary. Furthermore, additional research is required to determine the extent 
to which pTDP-43 pathological burden directly or indirectly relates to reductions  
in cortical thickness. In this study, our evaluation of cognitive performance was 
retrospective and limited to measures broadly assessing executive function and 
global cognition. Future studies using revised diagnostic criteria for 
frontotemporal dysfunction in ALS (Strong et al. 2017) and specialized 
assessment of cognitive function in patients with ALS, such as the Edinburgh 
Cognitive and Behavioral ALS Screen (Abrahams et al. 2014), are necessary to 
also assess impairments in other domains including language and behavior. 
Here, we focus on genetic contributions to frontotemporal disease in sporadic 
ALS. However, environmental factors such as those associated with cognitive 
reserve have been demonstrated to influence frontotemporal disease 
neuroanatomy in FTD (Massimo et al. 2018; Massimo et al. 2015; Placek et al. 
2016), also when considered in addition to genetic polymorphisms (Premi et al. 
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2017). Additional study is necessary to examine frontotemporal disease in 
sporadic ALS relative to both genetic polymorphisms and environmental factors 
associated with cognitive reserve. 
With these caveats in mind, our research demonstrates converging 
clinical, neuroimaging, and pathologic evidence supporting the hypothesis that 
the common genetic polymorphism rs12608932 contributes to frontotemporal 
disease phenotype in sporadic ALS. These findings stimulate investigation into 
additional genetic contributors to the nature of disease in sporadic ALS, and 
suggest their importance in prognostic consideration and treatment trials in 
patients with ALS. 
86 
 
Table 6. Demographic, clinical, and genetic information for neuroimaging and 
ADNI cohorts. 
 
 ALS Controls ADNI Controls 
N (F) 109 (44) 113 (52) 84 
Age, Y 59.54 (10.96) 61.54 (8.73) 75.44 (6.40) 




































Disease duration, M 38.67 (34.25) - - 
ALSFRS-R 33.81 (7.39) - - 









































Abbreviations: Alzheimer’s Disease Neuroimaging Initiative – ADNI; ALS 
Functional Rating Scale-Revised - ALSFRS-R; Mini-Mental State Exam – MMSE 
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Table 7. Demographic, clinical, and genetic information for autopsy cohort. 
 
  
ALS (entire cohort) 
ALS 
(no neuroimaging) 
N (F) 102 (40) 81 (29) 
Age at Death, Y 65.01 (10.83) 66.21 (10.99) 











Education, Y 15.18 (3.48) 14.76 (3.44) 
Disease duration at Death, 
Y 
4.83(4.98) 4.87(5.42) 
rs12608932 genotypes, N   
AA 38 30 
AC 47 39 
CC 17 12 
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Table 8. Regions of reduced cortical thickness for ALS relative to controls and 
associated with rs12608932 genotype in ALS. 
 
Neuroanatomic region (BA) L   MNI Coordinates T p Voxels 
/ x y z statistic value 
R 
Reduced cortical thickness in ALS relative to controls1: 25627 
Insular Cortex (13) R 40 22 0 6.72 0.0006  
Inferior Frontal Gyrus (45) L -32 28 2 6.18 0.0001  
Dorsolateral Prefrontal Cortex (9) - 0 46 18 6.12 0.0001  
Inferior Frontal Gyrus (45) R 34 22 8 5.96 0.0007  
Ventromedial Orbital Frontal Cortex (11) R 12 14 -20 5.91 0.0001  
Ventromedial Orbital Frontal Cortex (11) L -12 14 -18 5.79 0.0001  
Middle Temporal Gyrus (21) R 64 -32 10 3.54 0.004  
Reduced cortical thickness associated with rs12608932 minor allele in ALS: Additive model 
Anterior Temporal Lobe (38) R 34 10 -40 3.08 0.002 56 
Ventromedial Prefrontal Cortex (11) L -20 26 -24 3.21 0.001 27 
Middle Temporal Gyrus (22) L -50 -10 -12 2.88 0.003 24 
Dorsal Prefrontal Cortex (10) L -28 44 28 3.56 0.001 23 
Ventromedial Prefrontal Cortex (11) R 16 16 -24 3.66 0.001 21 
Reduced cortical thickness associated with rs12608932 minor allele in ALS: Recessive model 
Anterior Temporal Lobe (20) R 30 10 -44 3.50 0.001 238 
Middle Temporal Gyrus (21) L -50 -10 -14 4.04 0.001 83 
Anterior Temporal Lobe (20) L -56 -8 -28 3.56 0.001 62 
Premotor Cortex (6) L -50 2 42 3.90 0.001 52 
Dorsolateral Prefrontal Cortex (9) R 32 48 34 3.23 0.001 44 
Primary Motor Cortex (4) R 48 -12 40 3.07 0.001 39 
Superior Temporal Cortex (22) R 66 -36 10 3.30 0.001 35 
Orbital Prefrontal Cortex (11) R 8 34 -8 2.81 0.001 31 
Orbital Prefrontal Cortex (11) L -20 30 -24 3.23 0.001 31 
Ventromedial Prefrontal Cortex (47) R 30 22 4 3.45 0.001 30 
Hippocampus (54) R 30 -38 2 2.56 0.003 30 
Insula (13) R 36 -12 2 2.88 0.001 29 
Anterior Premotor Cortex (8) R 36 28 48 4.00 0.001 25 
Dorsal Prefrontal Cortex (10) L -34 52 16 3.16 0.001 25 
Middle Temporal Gyrus (21) R 50 8 -20 2.97 0.003 25 
Abbreviations: BA = Brodmann area; L/R = Left/Right; MNI = Montreal 
Neurological Institute 
Note.1 Cortical regions identified from peak voxel coordinates in an effort to 
describe sub-peaks within a larger, contiguous cluster. 
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Figure 4. Reduced cortical thickness associated with rs12608932 genotype. 
Analyses were restricted to regions of reduced cortical thickness identified in 
sporadic ALS (N=109) relative to healthy controls (N= 113) (light blue regions in 
A and B). A) Patients with sporadic ALS who are carriers of the minor allele (C) 
exhibited greater reduction of cortical thickness in dorsal prefrontal, ventromedial 
prefrontal, anterior temporal, and middle temporal cortices (regions indicated in 
red-yellow heatmap). B) Patients with sporadic ALS who are homozygous (CC) 
or heterozygous (AC) for the minor allele exhibited greater reduction of cortical 
thickness in the frontal and temporal cortices (regions indicated in red-yellow 
heatmap). Heatmaps indicate the associated T-statistic for each voxel, with 











































Figure 5. Greater burden of pTDP-43 pathology associated with rs12608932 
genotype. Box and whisker plots of pTDP-43 pathologic burden in our sporadic 
ALS autopsy cohort (N=102) show that minor allele homozygotes (CC) and 
heterozygotes (AC) feature greater burden of pathology in the middle frontal 
cortex. Minor allele homozygotes but not minor allele heterozygotes also feature 
















































































































Machine learning suggests polygenic contribution to cognitive dysfunction 
in amyotrophic lateral sclerosis 
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Amyotrophic lateral sclerosis (ALS) is a multi-system disease characterized 
primarily by progressive muscle weakness. Cognitive/behavioral dysfunction is 
observed in as many as 50% of patients, however factors influencing risk for 
cognitive dysfunction remain elusive. Using sparse canonical correlation analysis 
(sCCA), an unsupervised machine-learning technique, we observed that single 
nucleotide polymorphisms collectively associate with baseline cognitive 
performance in 327 ALS patients from the multicenter Clinical Research in ALS 
and Related Disorders for Therapeutic Development (CReATe) consortium. We 
demonstrate that a polygenic risk score derived using sCCA relates to 
longitudinal cognitive decline in the same cohort, and also to in vivo cortical 
thinning in the orbital frontal cortex, anterior cingulate cortex, lateral temporal 
cortex, premotor cortex, and hippocampus (N=114); as well as post mortem 
motor cortical neuronal loss (N=88) in independent ALS cohorts from the 
University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Our 
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findings suggest that common genetic polymorphisms may exert a polygenic 






As many as half of patients with amyotrophic lateral sclerosis (ALS) manifest 
progressive decline in cognition consistent with extra-motor frontal and temporal 
lobe neurodegeneration, including 14% also diagnosed with frontotemporal 
dementia (FTD) (Montuschi et al. 2015; Beeldman et al. 2016). Comorbid 
cognitive dysfunction is a marker of poorer prognosis in this fatal disease and 
confers risk for more rapid functional decline, shorter survival, and greater 
caregiver burden (Elamin et al. 2013; Crockford et al. 2018; Hu et al. 2013; Caga 
et al. 2019). While linkage analysis and genome-wide association studies 
(GWAS) have identified rare causal mutations (DeJesus-Hernandez et al. 2011; 
Renton et al. 2011; Van Deerlin et al. 2008; Freischmidt et al. 2015) and common 
risk loci (van Rheenen et al. 2016; Nicolas et al. 2018; van Es et al. 2009; 
Diekstra et al. 2014; Karch et al. 2018) linking ALS and FTD, whether and how 
identified variants relate to phenotypic heterogeneity, including in cognition, 
remain largely unexplored. 
The genetic landscape of ALS is largely characterized by ‘apparently 
sporadic’ disease occurring in 90% of patients with neither a known family 
disease history nor an identifiable pathogenic mutation (Turner et al. 2017). 
Population-based studies estimate that only 5-10% of non-familial and 40-50% of 
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familial ALS cases can be attributed to known pathogenic mutations (Umoh et al. 
2016) (e.g. C9ORF72 (Renton et al. 2011; DeJesus-Hernandez et al. 2011), 
NEK1 (Kenna et al. 2016), SOD1 (D. R. Rosen et al. 1993)), but GWAS have 
revealed many loci of common genetic variation that confer risk for ALS and 
FTD. Indeed, recent evidence, supports a polygenic contribution to disease risk 
from common genetic variants (McLaughlin et al. 2017; Ciga et al. 2019). These 
include the largest ALS GWAS to-date which newly identified risk variants in the 
KIF5A gene (Nicolas et al. 2018), and genome-wide conjunction and conditional 
false discovery rate (FDR) analyses demonstrating shared genetic contributions 
between ALS and FTD from common single nucleotide polymorphisms (SNPs) at 
known and novel loci (Karch et al. 2018). 
An accumulating body of research suggests that SNPs associated with 
risk of ALS and FTD demonstrate quantitative trait modification of patient 
phenotype. For example, a SNP in identified as a risk locus for ALS and FTD  
was found to contribute to cognitive decline, in vivo cortical degeneration in the 
prefrontal and temporal cortices, and post mortem pathologic burden of 
hyperphosphorylated TAR-DNA binding protein [43 kDa] (TDP-43) in the middle 
frontal, temporal, and motor cortices (Placek et al. 2019). Another SNP identified 
as a risk locus for FTD with underlying TDP-43 pathology was additionally 
associated with cognition in patients with ALS (Vass et al. 2011). Others have 
recently demonstrated shared polygenic risk between ALS and other traits (e.g. 
smoking, education) and diseases (e.g. schizophrenia) (Ciga et al. 2019; 
McLaughlin et al. 2017; Hagenaars et al. 2018), suggesting that a single variant 
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is unlikely to fully account for observed disease phenotype modification. 
Presently there are no published studies evaluating polygenic contribution to 
cognitive dysfunction in ALS. 
Here we employed an unsupervised machine-learning approach, sparse 
canonical correlation analysis (sCCA), to identify and evaluate a potential 
polygenic contribution to cognitive dysfunction in ALS. Traditional approaches for 
constructing polygenic scores identify variants associated with disease risk 
through GWAS in a univariate manner, and then compute the sum of alleles at 
each identified variant, weighted by their effect sizes. In this study, we used data- 
driven sCCA to identify polygenic associations with a continuous phenotype of 
cognitive performance in ALS. This method employs sparsity to select maximally- 
contributing variants and assigns corresponding weights based on model 
contribution with minimal a priori assumptions. We used sCCA to derive a 
polygenic risk score for cognitive dysfunction in a large longitudinal cohort of 
cognitively characterized patients with ALS or a related disorder participating in 
the Phenotype-Genotype-Biomarker (PGB) study of the Clinical Research in ALS 
and Related Disorders for Therapeutic Development (CReATe) consortium. We 
then evaluated independent neuroimaging and autopsy cohorts of patients with 
ALS from the University of Pennsylvania Integrated Neurodegenerative Disease 
Biobank (UPenn Biobank) (Toledo et al. 2014) to evaluate whether polygenic risk 
for cognitive dysfunction also relates to in vivo cortical neurodegeneration and ex 
vivo cortical neuronal loss and TDP-43 pathology. We focused our investigation 
on SNPs achieving genome-wide significance in the largest published ALS 
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GWAS (Nicolas et al. 2018), and SNPs identified as shared risk loci for both ALS 
and FTD (Karch et al. 2018). We hypothesized that a sparse multivariate 
approach would reveal a subset of genetic loci associated with cognitive 
dysfunction profiles in ALS in a polygenic manner, and that follow-up analyses in 
independent neuroimaging and autopsy cohorts would converge to characterize 





Heterogeneity of baseline cognitive and motor phenotype in ALS patients. 
Smaller-scale studies have shown that ALS patients have impairments in 
executive, verbal fluency, and language domains, but with relative sparing of 
memory and visuospatial function (Crockford et al. 2018). The Edinburgh 
Cognitive and Behavioral ALS Screen (ECAS) was developed to measure 
cognitive function minimally confounded by motor disability and includes an 
“ALS-Specific” score that captures impairments in language, executive function, 
and verbal fluency domains that are frequently observed in ALS patients, and an 
“ALS-Non-Specific” score that captures less frequently observed impairments in 
memory and visuospatial function, in addition to overall performance  (ECAS 
Total score) (Abrahams et al. 2014). To measure the extent of heterogeneity in 
cognitive dysfunction, we evaluated 327 patients with ALS or a related disorder 
(e.g., ALS-FTD, primary lateral sclerosis (PLS), progressive muscular atrophy 
(PMA)) participating in the PGB study of the CReATe consortium 
(NCT02327845) (Table 9). We used linear mixed-effects (LME) to model 
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variability between individuals in baseline performance and rate of decline on the 
ECAS (Total Score, ALS-Specific Score, ALS-Non-Specific Score, and scores for 
each individual cognitive domain), and on clinical measures of physical disability 
on the ALS Functional Rating Scale – Revised (ALSFRS-R), and clinician ratings 
of upper motor neuron (UMN) and lower motor neuron (LMN) symptom severity; 
each model included covariate adjustment for potential confounders including 
age, education, bulbar onset, and disease duration. We confirmed that cognitive 
and motor performance at baseline are heterogeneous across individuals (Figure 
6A), and correlation analyses suggested that this is independent of disability in 
physical function or clinical burden of UMN/LMN signs (all R<0.2; Figure 6B). 
Together this establishes the heterogeneity of baseline and longitudinal cognitive 
and motor phenotypes within the PGB cohort. 
 
 
Multivariate analyses indicate polygenic contributions to baseline cognitive 
performance. 
To identify potential polygenic contributions to cognitive impairment in ALS we 
employed sCCA (Witten, Tibshirani, and Hastie 2009), an unsupervised 
machine-learning approach enabling identification of multivariate relationships 
between a dataset of one modality (e.g. genetic variables including allele dosage 
of SNPs) and another modality (e.g. clinical measures of motor and cognitive 
function). Traditional CCA identifies a linear combination of all variables that 
maximize the correlation between datasets, resulting in an association of 
variables from one dataset (e.g., SNPs) and variables from another dataset (e.g., 
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clinical scores) (Witten, Tibshirani, and Hastie 2009). The “sparse” component of 
sCCA additionally incorporates an L1 penalty that shrinks the absolute value of 
the magnitude of coefficients to yield sparse models (i.e. models with fewer 
variables) such that some coefficients are zero, and the variables associated with 
them are effectively eliminated from the model. As a result, variables that 
contribute little variance to the model are dropped and instead of a linear 
combination of all model variables, we are able to identify a data-driven subset of 
variables from one dataset that relate to a subset of variables from another 
dataset. Unstandardized regression coefficients resulting from sCCA serve as 
canonical weights indicating the direction and strength of the relationships 
between selected variables. 
We evaluated an allele-dosage dataset comprised of 33 SNPs identified 
as shared risk loci for both ALS and FTD (Karch et al. 2018), and 12 SNPs 
identified as risk loci for ALS from the largest published case-control GWAS 
(Nicolas et al. 2018), with the latter chosen to include loci associated with ALS 
but not specifically with FTD (Figure 6C; Table 11). We included the first two 
principle components from a PCA and binary variables for sex, C9ORF72 repeat 
expansion status, and other mutation status (e.g. SOD1) in this dataset to 
account for inter-individual genetic differences in population structure, sex, and 
mutation status. We then used sCCA to examine the association between this 
genetic dataset and a dataset comprised of adjusted baseline clinical 




After optimizing model sparsity parameters (Figure 7), we ran sCCA 
10,000 times and employed random bootstrapped subsamples of 75% of 
participants in each iteration (Figure 8). We then calculated the median canonical 
correlation, the median canonical weight for each genetic variable, and the 
proportion of times each clinical feature was chosen out of 10,000 iterations as a 
percentage. We report percentages rather than median canonical weight for 
clinical features because the optimized L1 parameter for the clinical dataset was 
the most stringent (i.e. 0.1), thus resulting in only one variable from the clinical 
dataset being chosen in each of the 10,000 iterations. 
To assess model performance under the null hypothesis (no association 
between genetic factors and clinical phenotypes), we similarly ran 10,000 
bootstrap sCCAs using the same L1 and subsampling parameters and in each 
model iteration we randomly permuted each dataset 100 times. We also 
examined the proportion of times each variable was selected by this null model 
(i.e. achieving a non-zero canonical weight), and defined a p value for the true, 
unpermuted model by calculating the probability of observing a canonical 
correlation greater than or equal to the median canonical correlation under sCCA 
modeling of the true data relative to the canonical correlations observed under 
null sCCA modeling of randomly permuted data. 
We observed that a subset of 29 genetic variables were correlated with a 
single clinical feature, achieving a median canonical correlation between the two 
datasets of R=0.35 (95% Confidence Interval: 0.23, 0.42); p=0.019) (Figure 9, 
Figure 10). Over the 10,000 iterations, the most frequently selected clinical 
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variable was the ECAS ALS-Specific score (percentage of times selected: 37%), 
followed by the ECAS Total (29%), Executive Function (17%), Language (9.5%), 
Verbal Fluency (2.3%), ALS-Specific (2.2%), Memory (2%), and Visuospatial 
(0.34%) scores. The ALSFRS-R and UMN and LMN assessments were each 
selected in less than 0.05% of the model iterations. By contrast, performance of 
sCCA modeling under the null hypothesis demonstrated that each clinical 
variable was selected in a largely equal proportion of iterations (all variables 
ranging 5.9% to 9.4%), demonstrating that the true sCCA modeling selected 
cognitive and not motor features beyond what would be expected by chance 
(Figure 11A). 
Of the 29 selected genetic variables, the 12 most highly weighted were 
rs1768208 and rs9820623 (MOBP), rs7224296 (NSF), rs538622 (ERGIC1), 
rs10143310 (ATXN3), rs6603044 (BTBD1), rs4239633 (UNC13A), rs2068667 
(NFASC), rs10488631 (TNPO3), rs11185393 (AMY1A), rs3828599 (GPX3), and 
sex. Twenty-seven of the 29 genetic variables selected were SNPs, and 85% of 
model-selected SNPs (23/27) were shared risk loci for ALS and FTD (Karch et al. 
2018). Modeling under the null revealed that each genetic variable achieved a 
largely equal median weight, and thus there were no stronger model  
contributions from any subset of genetic variables (Figure 11B). The association 
of genetic variants most frequently with the ECAS ALS-Specific score suggests 
polygenic contribution to impairment in domains of cognition frequently impaired 
in patients with ALS (e.g. language, verbal fluency, and executive function) that 





Polygenic score captures baseline cognition as well as longitudinal rate of 
cognitive decline, but not motor decline. 
Next we investigated potential polygenic contributions to rate of decline in motor 
and cognitive performance in the CReATe PGB cohort. Investigation of baseline 
performance may only capture differences in cognitive impairment at a single 
(somewhat arbitrary) point in time, but not differences in the trajectory of 
cognitive decline over time. 
To evaluate association with longitudinal decline, we first calculated a 
weighted polygenic score (wPGS) by computing a weighted sum of allele dosage 
for each individual multiplied by the median canonical weights for each genetic 
variant resulting from the prior sCCA. Spearman rank-order correlations between 
the wPGS and adjusted baseline estimates of the 4 clinical features selected in 
10% or more of the 10,000 iterations (e.g. ECAS ALS-Specific, Total, Executive 
Function, and Language scores) resulted in correlation values similar to the 
canonical correlation observed from sCCA (e.g. for ECAS ALS-Specific: 
rs(329)=-0.34, p=2.4×10-10) (Figure 12A), suggesting construct validity. 
We then conducted Spearman’s rank order correlations between the 
wPGS and adjusted rate of decline on each measure of cognitive and motor 
performance using a Bonferroni family-wise error correction. To obtain adjusted 
rates of decline, we extracted individual slope estimates from prior LME (see 
above) for the 277 individuals (85%) with 2 or more observations on the ECAS, 
ALSFRS-R, and UMN and LMN assessments. We observed significant negative 
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relationships between the wPGS and rate of decline on ECAS ALS-Specific 
(rs(277)=-0.21, p=5.3×10-3), ALS-NonSpecific (rs(277)=-0.19, p=0.016), and 
Total scores (rs(277)=-0.26, p=8.1×10-5) (Figure 12B), but not on the ALSFRS-R 
or UMN and LMN scores (all p >0.9). These findings suggest polygenic 
contribution to rate of cognitive – but not motor – decline from the SNPs 




Polygenic score associates with cortical thinning in the UPenn Biobank. 
Cognitive dysfunction in ALS, including performance on the ECAS, has 
previously been attributed to sequential disease progression rostrally and 
caudally from the motor cortex (Lulé et al. 2018; Agosta et al. 2016; Müller and 
Kassubek 2018) and advancing disease stage (Crockford et al. 2018). To 
evaluate the neuroanatomic basis for polygenic contribution to cognitive 
performance in patients with ALS, we applied the wPGS score derived in the 
CReATe PGB Cohort to an independent cohort of patients with ALS from the 
UPenn  Biobank. We used voxel-wise in vivo measures of reduced cortical 
thickness (in mm3) in ALS patients. Cross-sectional measurements of cortical 
thickness were derived from T1-weighted magnetic resonance imaging (MRI) in 
114 patients with ALS and 114 age, sex, and education-matched healthy controls 
who were recruited for research from UPenn (Table 10A). Nonparametric 
modeling using 10,000 random permutations revealed extensive reduction of 
cortical thickness bilaterally in the frontal and temporal cortices of patients with 
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ALS relative to healthy controls (Table 12, Figure 13A). 
 
After identifying regions of reduced cortical thickness in patients with ALS, 
we investigated whether the wPGS derived from sCCA modeling in the CReATe 
PGB cohort contributed to magnitude of reduced cortical thickness in the 
independent UPenn Biobank neuroimaging cohort. Nonparametric modeling 
using 10,000 random permutations with adjustments for potential confounds in 
age, disease duration, and scanning acquisition revealed that a higher wPGS  
(i.e. greater risk) associated with reduced cortical thickness in the orbital 
prefrontal cortex, anterior cingulate cortex, premotor cortex, lateral temporal 
cortex, and hippocampus (Figure 13B, Table 12). Identified frontal and temporal 
lobe cortical regions are known to support the domains of cognitive dysfunction 
characterized by the ECAS (Lulé et al. 2018). These findings provide a potential 
neuroanatomical basis for observed polygenic relationships between the wPGS 
and baseline cognitive performance and rate of decline, and are consistent with 
prior associations of cortical neurodegeneration with cognitive dysfunction in 
patients with ALS (Agosta et al. 2016). 
 
 
Polygenic score associates with neocortical neuronal loss in the UPenn Biobank. 
To complement these in vivo neuroanatomical data, we also explored whether 
polygenic risk for cognitive dysfunction associated with post-mortem anatomical 
distribution of neuronal loss and TDP-43 pathology. We assessed the magnitude 
of neuronal loss and TDP-43 pathological inclusions on an ordinal scale in tissue 
sampled from the middle frontal, cingulate, motor, and superior / middle temporal 
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cortices in 88 autopsy cases with confirmed ALS due to underlying TDP-43 
pathology (Table 10B). We conducted ordinal logistic regression with covariate 
adjustment for age at death and disease duration and found that ALS cases with 
higher wPGS were 2.05 times more likely (95% CI: 1.05, 4.10; p=0.0043) to have 
greater neuronal loss in the motor cortex relative to ALS cases with a lower 
wPGS (Figure 13C); older age at death and longer disease duration were not 
found to influence likelihood of greater neuronal loss (both p>0.05). We observed 
no statistically significant associations between the wPGS and neuronal loss in 
any other region, or between the wPGS and TDP-43 pathology in any other 
region (all p values >.1). These findings suggest that polygenic risk for cognitive 
dysfunction is associated with the neuroanatomic distribution of neuronal loss in 





In this study, we evaluated polygenic contributions to cognitive dysfunction in 
patients with ALS by employing machine learning. We identified polygenic risk for 
cognitive dysfunction from genetic variables associated with risk of ALS and 
FTD, which we further investigated through quantitative-trait evaluations of two 
independent ALS cohorts with in vivo neuroimaging and post-mortem 
neuropathology data. Our results indicate a polygenic contribution to the 
presence and rate of decline of cognitive dysfunction in domains specifically 
impaired in ALS. Converging evidence from independent cohorts further 
demonstrates the generalizability of polygenic contribution to biologically- 
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plausible associations including reduced in vivo cortical thickness and post- 
mortem cortical neurodegeneration, including in the prefrontal and temporal 
cortices. These findings contribute novel evidence in support of polygenic 
contribution to cognitive dysfunction in ALS, quantitative anatomic 
characterization of identified polygenic risk associated with cognitive dysfunction, 
and further detailed phenotypic evidence for genetic overlap between ALS and 
FTD. Below, we highlight clinical, biological, and methodological implications for 
our observations. 
Our findings add to an increasing body of evidence for genetic contribution 
to phenotypic variability in ALS, and support the idea that polygenic variation 
accounts for, at least a portion, of variability in cognitive dysfunction and cortical 
disease burden in ALS. While cognitive impairment has been more frequently 
linked to genetic mutations causally associated with ALS, such as C9ORF72 
repeat expansions (Byrne et al. 2012), studies examining individual variants have 
implicated SNPs as risk factors for ALS and/or FTD (Placek et al. 2019; Vass et 
al. 2011). However, mounting evidence suggests that there are polygenic, rather 
than single allele, modifiers of disease risk and phenotype in ALS and related 
neurodegenerative diseases (Hagenaars et al. 2018; McLaughlin et al. 2017; 
Ciga et al. 2019). Our observation of 27 SNPs collectively associated most 
frequently with the ECAS ALS-Specific score, a combined measure of executive, 
language, and verbal fluency domains most commonly affected in ALS, is 
consistent with the idea of polygenic contribution to phenotypic variability in ALS. 
Notably, our observed polygenic association in the CReATe PGB Cohort appears 
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specific to cognitive variability: we demonstrate relative independence of 
cognitive performance and motor disease severity (i.e. UMN or LMN symptom 
assessments, functional performance on the ALSFRS-R) and observe no 
evidence for polygenic association with motor disease severity. This suggests 
that, in this study, polygenic risk for cognitive dysfunction does not appear to be 
confounded by motor disease severity. 
Of the 27 identified SNPs, the majority (85%) are shared risk loci for ALS 
and FTD (Karch et al. 2018). SNPs in or near the MOBP, NSF, ATXN3, ERGIC1, 
and UNC13A genes were among those with the strongest model contributions 
(i.e. with the highest canonical weights). Relative to random permutations, the 
frequency of the selection of these ALS and FTD loci outweighed their selection 
by chance and outweighed the selection of ALS-only risk genotypes, 
emphasizing the relative contribution of polygenic overlap between ALS and 
FTD. Furthermore, these results suggest a conceptual distinction between 
genetic risk for disease and genetic risk for phenotypic differences within a 
disease. Two of these loci in or near the MOBP gene (rs9820623, rs1768208) 
were amongst the most heavily weighted. Our group has previously shown that 
SNPs mapped to MOBP, including rs1768208, relate to regional 
neurodegeneration in patients with sporadic forms of FTD and shorter survival in 
FTD patients with underlying tau or TDP-43 pathology (Irwin, McMillan, et al. 
2014; McMillan et al. 2014). Our group has also demonstrated an additive dose- 
response relationship between the minor allele of rs12608932 (D’) in UNC13A 
and in vivo cortical thinning in the dorsal prefrontal cortex, greater burden of 
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TDP-43 pathology in the middle frontal and motor cortices at autopsy, and worse 
performance on a measure of working memory associated with executive 
function (Placek et al. 2019). rs538622 near ERGIC1, originally identified through 
conditional FDR as a shared risk locus for ALS and FTD, has also been 
previously demonstrated to contribute to quantitative trait modification in ALS by 
relating to reduced expression of the protein BNIP1 in ALS patient motor neurons 
(Karch et al. 2018). Other top-weighted variants near NSF and ATXN3 indicate 
potential biological plausibility: rs10143310 is found near ATXN3 which encodes 
a de-ubiquitinating enzyme, and polyglutamine expansions in ATXN3 cause 
spinocerebellar ataxia – type 3 (Burnett, Li, and Pittman 2003). rs7224296 near 
NSF tags the MAPT H1 haplotype (Yokoyama et al. 2017) and is associated with 
increased risk for FTD syndromes including progressive supranuclear palsy and 
corticobasal degeneration (Ferrari et al. 2017), as well as Alzheimer’s and 
Parkinson’s diseases (Desikan et al. 2015). 
While the mechanism of polygenic contribution to cognitive dysfunction in 
ALS requires further investigation, we speculate based on our findings that 
identified SNPs may contribute to neuroanatomic disease burden. A weighted 
polygenic risk score derived from the observed multivariate genotype-phenotype 
correlation in the CReATe PGB cohort showed robust relationships in 
independent validation cohorts to both in vivo cortical thinning and post-mortem 
cortical neuronal loss. Anatomically, these findings were largely consistent with 
prior in vivo structural imaging studies of neurodegeneration associated with 
cognitive dysfunction and with ex vivo investigations of cortical thinning in ALS 
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(Lulé et al. 2018; Agosta et al. 2016; Prudlo et al. 2016). Thus, in addition to 
indicating polygenic contribution to cognitive dysfunction in ALS, our findings 
suggest a possible mechanism of observed findings via disease pathophysiology. 
Beyond the potential biological mechanism of identifying polygenic contributions 
to ALS disease heterogeneity, we additionally suggest that sCCA may provide 
a tool for defining polygenic factors of disease risk. While sCCA has been widely 
applied to imaging-genetic studies (Parkhomenko, Tritchler, and Beyene 2009), 
we are unaware of prior applications using sCCA to define and polygenic 
score based on rich clinical phenotypic and biomarker data. Traditional 
approaches to the generation of polygenic scores include using data from 
established, typically case-control GWAS, but practical considerations involve the 
selection of how many variants to include in a model and how to define the 
weights of an appropriate statistical model (Sugrue and Desikan 2019). Critically, 
rather than an arbitrary selection of variants and their weights, the sparsity 
parameter of sCCA facilitates an unsupervised, data-driven method to select the 
number of variants to include in the model and the canonical correlation provides 
data-driven weights to define the statistical model. The positive or negative 
direction of model-derived weights is potentially biologically informative, and 
could reflect ‘risk’ (i.e. positive weight) or ‘protective’ (i.e. a negative weight) 
effects. Further investigation is necessary to clarify the relationships between 
model-selected SNPs and model-derived canonical weight from both biological 
(e.g., some SNPs and/or genes may contribute more strongly to risk factors) and 
mathematical (e.g. weights may be constrained by minor allele frequency) 
108 
 
perspectives. Nonetheless, sCCA may provide an optimal method for future 
studies of polygenic variation and direct research efforts towards model-selected 
variants. 
Several limitations should be considered in the present study. Here, we 
focus our analysis on a hypothesized relatively small set of SNPs selected a 
priori from previous large-scale GWAS based on genome-wide association with 
ALS (Nicolas et al. 2018) or shared risk between ALS and FTD (Karch et al. 
2018). Other genetic variants not included in the present study may also 
contribute to cognitive dysfunction in ALS and related disorders, and future 
genome-wide or more broad genotype selection strategies (e.g., targeted 
pathways) are necessary to elucidate discovery of novel genetic contributions to 
cognition that have not been identified through prior case-control studies. 
However, since our focused SNP selection targets previously validated 
genotypes from GWAS studies, these larger scale studies necessitate further 
validation in independent cohorts, many of which are lacking the rich phenotype 
data needed to identify cognitive dysfunction. We derived a weighted polygenic 
score from bootstrap sCCA modeling to further investigate polygenic 
associations with longitudinal clinical and cognitive performance, and to 
investigate polygenic associations with in vivo and post-mortem disease 
neuroanatomy in independent ALS cohorts from the UPenn Biobank. While we 
define our polygenic score from sCCA using adjusted estimates of baseline 
cognitive and motor performance, future work using longitudinal data as the 
starting point to define polygenic associations may further elucidate genetic risk 
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for cognitive dysfunction in ALS. However, our finding that polygenic risk 
associated with baseline cognitive dysfunction also relates to longitudinal 
cognitive decline in the PGB cohort and relevant disease anatomy in 
independent cohorts suggests its relevance to longitudinal cognitive phenotypes 
in ALS. Previous critique of polygenic scores suggest calculation based on 
GWAS-defined odds ratios for univariate risk loci or undue influence by 
population variance limit their use in clinical and prognostic settings (Wald and 
Old 2019). To avoid these potential confounds, our computation of a weighted 
polygenic risk score is based on model-selected parameters derived from an 
analysis including all genetic variants and covariates for genetic mutation status 
and sex in an effort to account for multivariate genetic relationships. We also 
included the first two principal components in our model from a PCA conducted 
in the PGB CReATe cohort in an effort to account for differences in population 
heterogeneity (Price et al. 2006). 
Our analyses focused on the investigation of genetic contribution to 
cognitive dysfunction in ALS, yet it is well established that behavioral impairment 
is also part of the ALS spectrum disease (Lillo et al. 2010). Further research is 
necessary to investigate polygenic risk for behavioral dysfunction in ALS, and 
whether loci included in our calculated polygenic score confer risk for both 
cognitive and behavioral dysfunction. While this study demonstrates converging, 
multimodal evidence for polygenic risk in independent neuroimaging and autopsy 
cohorts, replication in additional, large cohorts that allow for robust cross- 
validation is warranted, however, alternative datasets that contain detailed 
110 
 
genetic and cognitive phenotyping for ALS are currently lacking, and the CReATe 
PGB cohort represents the largest of its kind. Future research investigating 
additional, large-scale patient cohorts with genetic and phenotypic data is 
necessary. 
With these limitations in mind, our research demonstrates converging 
clinical, neuroimaging, and pathologic evidence for polygenic contribution to 
cognitive dysfunction and cortical neurodegeneration in ALS. These findings 
should stimulate further investigation into polygenic risk for cognitive disease 
vulnerability in ALS and suggest their importance in prognostic consideration and 
treatment trials. More broadly, this work provides insight into genetic contribution 
to heterogeneous phenotypes in neurodegenerative disease and supports 





Participants: CReATe Consortium 
 
Participants consisted of 339 individuals clinically diagnosed by a board-certified 
neurologist with a sporadic or familial form of amyotrophic lateral sclerosis (ALS), 
amyotrophic lateral sclerosis with frontotemporal dementia (ALS-FTD), 
progressive muscular atrophy (PMA), or primary lateral sclerosis (PLS) who were 
enrolled and evaluated through the CReATe Consortium’s Phenotype-Genotype- 
Biomarker (PGB) study. All participants provided written informed consent. The 
PGB study is registered on clinicaltrials.gov (NCT02327845) and the University 
of Miami IRB (the central IRB for the CReATe Consortium) approved the study. 
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This study entails participant blood DNA samples available for genetic screening 
and longitudinal evaluation at regularly-scheduled visits (ALS, ALS-FTD, and 
PMA: 0 (baseline), 3, 6, 12, and 18 months; PLS: 0 (baseline), 6, 12, 18, and 24 
months). Participants were evaluated at each visit using the ALSFRS-R 
(Cedarbaum, Stambler, Malta, Fuller, Hilt, Thurmond, and Nakanishi 1999b) and 
alternate versions of the Edinburgh Cognitive and Behavioural ALS Screen 
(ECAS) (Abrahams et al. 2014). Upper motor neuron (UMN) and lower motor 
neuron (LMN) burden scores were calculated from a detailed elemental 
neuromuscular examination by summing within and across each spinal region 
resulting in a score ranging from 0 (none) to 10 (worst). Site (e.g. limb, bulbar) 
and date of motor symptom onset were recorded for each participant. We 
excluded nine individuals with missing or incomplete data that precluded 
subsequent analysis and, in an effort to avoid confounds associated with clear 
outliers, three individuals with extreme values at baseline on the ECAS 
Visuospatial Score (i.e. >5 standard deviations from group mean), resulting in a 
total of 327 participants. Of the nine excluded individuals with missing or 
incomplete data, one had no genotyping data available, one had no information 
for UMN burden, and seven had no information for date of motor symptom onset. 
 
 
Genotyping: CReATe Consortium 
 
Peripheral blood mononuclear cell DNA was extracted using the QIAamp DNA 
Blood Mini Kit Qiagen #51106 and quantified using the Quant-iT dsDNA Assay 
Kit (Life Technologies cat#Q33130). The DNA integrity was verified by agarose 
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gel electrophoresis (E-Gel, Life Technologies, cat#G8008-01). Unique samples 
were barcoded and whole genome sequencing (WGS) was performed at the 
HudsonAlpha Institute for Biotechnology Genomic Services Laboratory 
(Huntsville, Alabama) (HA) using Illumina HiSeq X10 sequencers to generate 
approximately 360 million paired-end reads, each 150 base pairs (bp) in length. 
Peripheral DNA was extracted from participant blood samples and screened for 
known pathogenic mutations associated with ALS and related diseases. 
Screening included repeat-primed PCR for C9ORF72 repeat expansions 
and WGS curated and validated via Sanger sequencing for pathogenic mutations 
associated with ALS and/or FTD in ANG, CHCHD10, CHMP2B, FUS, GRN, 
hnRNPA1, hnRNPA2B1, MAPT, MATR3, OPTN, PFN1, SETX, SOD1, SPG11, 
SQSTM1, TARDBP, TBK1, TUBA4A, UBQLN2, VCP. The PGB study also 
includes patients with hereditary spastic paraplegia (HSP) that were excluded in 
the current analysis, but we additionally screened individuals for pathogenic 
mutations in 67 additional genes associated with HSP and seven genes 
associated with distal hereditary motor neuropathy. 
Whole genome sequencing (WGS) data were generated using  paired-end 
 
150 bp reads aligned to the GRCh38 human reference using the Burrows- 
Wheeler Aligner (BWA-ALN v0.7.12)(Heng Li and Durbin 2010) and processed 
using the Genome Analysis Toolkit (GATK) best-practices workflow implemented 
in GATK v3.4.0 (McKenna et al. 2010). Variants for individual samples were 
called with HaplotypeCaller, producing individual variant call format files (gVCFs) 
that we combined using a joint genotyping step to produce a multi-sample VCF 
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(pVCF). Variant filtration was performed using Variant Quality Score 
Recalibration (VQSR), which assigns a score to each variant and a pass/fail label 
and evaluated this in the context of hard filtering thresholds (Minimum Genotype 
Quality (GQ)≥ 20, minimum mean depth value (DP)≥ 10). Variant annotation was 
performed using Variant Effect Predictor (VEP) (Hunt et al. 2018) and in-house 
pipelines including non-coding variant allele frequencies from Genome 
Aggregation Database (gnomAD).(Karczewski et al. 2019) In-house scripts were 
used to identify false positives resulting from paralogous mapping or/and gaps in 
the current human genome assembly. VCFs were further decomposed prior to 
analyses using the Decompose function of Vt (Tan, Abecasis, and Kang 2015). 
To control for population substructure, we additionally derived the first two 
principal components scores for each in the CReATe PBG cohort using principal 
components analysis (PCA) as implemented in Eigenstrat software (Price et al. 
2006). 
From the WGS data we extracted 45 hypothesized variants from WGS  
that previously achieved genome-wide significance for association with ALS 
(Nicolas et al. 2018) or joint association with ALS and FTD via GWAS (Karch et 
al. 2018). Proxy loci were genotyped (linkage disequilibrium (LD) R2 > 0.80) 
when genetic data were not available for previously-published loci. One locus, 
rs12973192, was common to both references, and another locus (rs2425220 
(Karch et al. 2018)) was excluded from analysis due to high level of missingness 
across samples; no LD proxy was identified. We then used Plink software 
(Purcell et al. 2007) to recode participant genotypes according to additive genetic 
114 
 
models (e.g. 0 = no minor allele copies, 1 = one minor allele copy, 2 = two minor 
allele copies), since the dominant or recessive nature of the loci included in this 
study remains unknown. 
 
 
Linear Mixed-Effects Modeling of the ECAS and clinical measures 
 
We conducted linear mixed-effects modeling of performance on the ECAS, 
ALSFRS-R, and UMN and LMN scores using the nlme package in R. Each 
model was fit using maximum likelihood. In addition to the ECAS Total Score, we 
analyzed Executive Function, Language, Verbal Fluency, Memory, and 
Visuospatial scores and summary scores (ALS-Specific score, ALS-Non-Specific 
score) each as dependent variables to analyze patient performance in separate 
cognitive domains and in clinically-grouped cognitive domains. Fixed effects 
included age at baseline visit (in years), lag between age of symptom onset and 
age at baseline visit (in years), college education (yes / no), bulbar onset (yes / 
no) and visit time-point (in months), and we included individual by visit time-point 
as random effects. This allowed us to obtain adjusted estimates of baseline 
performance (i.e. intercept) and rate of decline (i.e. slope) per individual, having 
regressed out potential confounding variables as fixed effects. 
We conducted Spearman’s rank-order correlations between baseline 
performance and rate of decline using a Bonferroni family-wise error correction 
for multiple comparisons. 
 
 
Sparse Canonical Correlation Analysis 
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We next conducted sparse canonical correlation analysis (sCCA) to select a 
parsimonious linear combination of variables that maximize the correlation 
between two multivariate datasets using the PMA package in R (Witten, 
Tibshirani, and Hastie 2009). The first dataset comprised scaled intercepts from 
each clinical variable per participant (i.e. adjusted baseline performance on the 
ALSFRS-R, UMN and LMN assessments, and ECAS). The second comprised 
minor allele counts per individual for each of the 45 SNPs (e.g. 0 = no minor 
allele copies, 1 = one minor allele copy, 2 = two minor allele copies), binary 
variables for sex (0 = Female, 1 = Male), C9ORF72 repeat expansion status (0 = 
noncarrier, 1 = carrier), and other mutation status (0 = noncarrier, 1 = carrier) 
and, in an effort to account for potential population differences in population 
variance we also included the raw estimates for the first two principle 
components per participant derived from a PCA conducted in the CReATe PGB 
cohort, which has previously been demonstrated to account for the majority of 
population structure (Price et al. 2006). 
We assumed standard (e.g. unordered) organization of each dataset, and 
selected regularization parameters for the sCCA analysis using a grid search of 
100 combinations of L1 values between 0 (most sparse) and 1 (least sparse) in 
increments of 0.1. We selected the combination of L1 values yielding the highest 
canonical correlation of the first variate for subsequent analysis, as similarly 
reported (Xia et al. 2018). 
Using these L1 parameters, we ran 10,000 bootstrap sCCAs and on each 
iteration employed randomly-generated subsamples comprising 75% of the PGB 
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cohort. From this, we calculated the median canonical correlation for sCCA and 
the median canonical weights for each variable. We utilize the median in these 
estimates rather than the maximum or mean value in an effort to avoid bias from 
outliers and to increase the reliability and reproducibility of model estimates. 
We next investigated model performance under a null hypothesis (i.e. no 
association between clinical and genetic datasets) by using randomly-permuted 
data. Using the same L1 parameters, we again ran 10,000 bootstrap sCCAs and 
on each iteration employed randomly-generated subsamples of 75% of 
participants; however, on each iteration we randomly permuted each dataset 100 
times using the randomizeMatrix function from the picante package in R. We 
calculated a p value by reporting the probability of observing a canonical 
correlation greater than or equal to the median canonical correlation under sCCA 
modeling of the true data relative to the canonical correlations observed under 
null sCCA modeling of randomly permuted data. We also examined the 
proportion (i.e. out of 10,000) of times each variable was selected by the model 





To evaluate the applicability of our sCCA model, we used the output of the model 
to calculate a weighted polygenic score (wPGS) for each individual by computing 
a weighted sum of allele dosage across all genotypes for each individual. 
Weights were derived for each genetic variable by using the median canonical 
weight over the 10,000 bootstrap sCCAs. 
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To investigate construct validity, we conducted Spearman’s rank-order 
correlations between the wPGS and adjusted estimates of baseline performance 
(i.e. LME-derived intercepts) on the most frequently selected clinical measure(s) 
selected from sCCA. 
To investigate longitudinal performance associated with the wPGS, we 
conducted Spearman’s rank-order correlations between the wPGS and adjusted 
rates of decline (i.e. LME-derived slopes) on all clinical measures using a 
Bonferroni familywise error correction for multiple comparisons. We restricted this 
analysis to CReATe participants with data at 2 or more timepoints (N=277 out of 
327 participants), or 84.7% of the participant cohort. 
 
 
Participants: UPenn Biobank neuroimaging cohort 
 
We retrospectively evaluated 114 patients with ALS and 114 healthy controls 
matched for age, sex, and education from the UPenn Biobank who were 
recruited for research between 2006 and 2019 from the Penn Comprehensive 
ALS Clinic and Penn Frontotemporal Degeneration Center (Table 10) (Toledo et 
al. 2014). Inclusion criteria for ALS patients consisted of complete genotyping at 
analyzed SNPs, white non-Latino racial and ethnic background (population 
diversity is known to influence allele frequencies across individuals), disease 
duration from symptom onset < 2.5 standard deviations from respective group 
means (to avoid confounds associated with clear outliers), and T1-weighted MRI. 
All patients were diagnosed with ALS by a board-certified neurologist (L.E., L.M., 
M.G., D.I) using revised El Escorial criteria (Brooks et al. 2000) and assessed for 
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ALS frontotemporal spectrum disorder using established criteria (Strong et al. 
2017); those patients enrolled in research prior to 2017 were retrospectively 
evaluated through chart review. All ALS patients and healthy controls participated 
in an informed consent procedure approved by an Institutional Review Board 
convened at UPenn. 
 
 
Participants: UPenn Biobank autopsy cohort 
 
We evaluated brain tissue samples from 88 ALS autopsy cases identified from 
the UPenn Biobank (Toledo et al. 2014) who were diagnosed by a board-certified 
neuropathologist (J.Q.T., E.B.L.) with ALS due to TDP-43 pathology using 
immunohistochemistry (Neumann et al. 2006) and published criteria (Mackenzie 
et al. 2011); this cohort included 21 patients from the ALS neuroimaging cohort. 
Inclusion criteria consisted of complete genotyping at analyzed SNPs, white non- 
Latino racial and ethnic background (population diversity is known to influence 
allele frequencies across individuals), disease duration from symptom onset < 
2.5 standard deviations from respective group means (to avoid confounds 
associated with clear outliers), and brain tissue samples from the middle frontal, 
motor, cingulate, and superior / temporal cortices, and the cornu ammonis 1 
(CA1) / subiculum of the hippocampus for analysis of neuronal loss and TDP-43 
pathology. Nine individuals were missing neuronal loss or TDP-43 pathology data 
for at least 1 sampled region (Table 13). 
 
 
Genetic Screening and SNP Genotyping: UPenn Biobank 
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DNA was extracted from peripheral blood or frozen brain tissue following the 
manufacturer’s protocols (Flexigene (Qiagen) or QuickGene DNA whole blood kit 
(Autogen) for blood, and QIAsymphony DNA Mini Kit (Qiagen) for brain tissue). 
All patients were screened for C9ORF72 hexanucleotide repeat expansions 
using a modified repeat-primed polymerase-chain reaction (PCR) as previously 
described (Suh et al. 2015). Of the remaining individuals, we evaluated family 
history using a 3-generation pedigree history as previously reported (Wood et al. 
2013). For cases with a family history of the same disease we sequenced 45 
genes previously associated with neurodegenerative disease, including genes 
known to be associated with ALS (e.g. SOD1 (D. R. Rosen et al. 1993), TBK1 
(Freischmidt et al. 2015)). Sequencing was performed using a custom-targeted 
next-generation sequencing panel (MiND-Seq) (Toledo et al. 2014) and analyzed 
using Mutation Surveyor software (Soft Genetics, State College, PA). 
For analyses of UPenn Biobank samples, we genotyped peripheral or 
brain cerebellum DNA of each case using the Illumina Infinium Global Screening 
Array through the Children’s Hospital of Philadelphia (CHOP) Center for Applied 
Genomics Core according to manufacturer’s specifications. PLINK (Purcell et al. 
2007) was then used to remove variants with <95% call rate, Hardy-Weinberg 
equilibrium (HWE) p-value < 10-6 and individuals with >5% missing genotypes. 
Using the remaining genotypes from samples passing quality control, we 
performed genome-wide imputation of allele dosages with the Haplotype 
Reference Consortium reference panel r1.1 (McCarthy et al. 2016) on the 
Michigan Imputation Server (Das et al. 2016) to predict genotypes at 
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ungenotyped genomic positions, applying strict pre-phasing, pre-imputation 
filtering, and variant position and strand alignment control. 
 
 
Neuroimaging Processing and Analyses 
 
High-resolution T1-weighted MPRAGE structural scans were acquired for 
neuroimaging participants using a 3T Siemens Tim Trio scanner with an 8- 
channel head coil, with T=1620ms, T=3.09ms, flip angle=15°, 192x256 matrix, 
and 1mm3 voxels. T1-weighted MRI images were then preprocessed using 
Advanced Normalization Tools (ANTs) software (Tustison et al. 2014). Each 
individual dataset was deformed into a standard local template space in a 
canonical stereotactic coordinate system. ANTs provide a highly accurate 
registration routine using symmetric and topology-preserving diffeomorphic 
deformations to minimize bias toward the reference space and to capture the 
deformation necessary to aggregate images in a common space. Then, we used 
N4 bias correction to minimize heterogeneity (Tustison et al. 2010) and the ANTs 
Atropos tool to segment images into six tissue classes (cortex, white matter, 
cerebrospinal fluid, subcortical grey structures, brainstem, and cerebellum) using 
template-based priors and to generate probability maps of each tissue. Voxel- 
wise cortical thickness was measured in millimeters (mm3) from the pial surface 
and then transformed into Montreal Neurological Institute (MNI) space, smoothed 
using a 3 sigma full-width half-maximum Gaussian kernel, and downsampled to 
2mm isotropic voxels. 
We used randomise software from FSL to perform nonparametric, 
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permutation-based statistical analyses of cortical thickness images from our 
neuroimaging cohort. Permutation-based statistical testing is robust to concerns 
regarding multiple comparisons since, rather than a traditional assessment of two 
sample distributions, this method assesses a true assignment of factors (e.g. 
wPGS) to cortical thickness relative to many (e.g., 10,000) random assignments 
(Winkler et al. 2014). 
We first identified reduced cortical thickness in ALS patients relative to 
healthy controls. We constrained analysis using an explicit mask restricted to 
high probability cortex (>0.4) and report clusters that survive p<0.05 threshold- 
free cluster enhancement (TFCE) (Smith and Nichols 2009) corrected for family- 
wise error relative to 10,000 random permutations. 
We next evaluated whether wPGS relates to magnitude of reduced 
cortical thickness, covarying for age, disease duration, and scanner acquisition in 
an effort to control for factors associated with reduced cortical thickness but not 
specifically associated with polygenic risk. We constrained analysis to an explicit 
mask including regions of reduced cortical thickness identified relative to healthy 
controls (see above). We report clusters that survive uncorrected p<0.01 with a 
cluster extent threshold of 10 voxels relative to 10,000 random permutations; we 
employ an uncorrected threshold to minimize the chance of Type II error (not 
observing a true result). 
 
 
Neuropathology Processing and Analyses 
 
Extent of neuronal loss and of phosphorylated TDP-43 intraneuronal inclusions 
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(dots, wisps, skeins) in sampled regions from the middle frontal, cingulate, motor, 
and superior / middle temporal cortices, and the CA1 / subiculum of the 
hippocampus were assessed on a semi-quantitative ordinal scale: 0=none/rare, 
1=mild, 2=moderate, 3=severe/numerous. All neuropathological ratings were 
performed by an expert neuropathologist (J.Q.T., E.B.L.) blinded to patient 
genotype. We conducted ordinal logistic regression using the MASS package in 
R to investigate whether extent of neuronal loss rated using Hematoxylin and 
eosin (H&E) and burden of TDP-43 pathology rated using mAbs p409/410 or 171 
(Lippa et al. 2009; Neumann et al. 2009) immunohistochemistry differed 
according to wPGS, covarying for age and disease duration. 
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Table 9: Demographics of ALS patients from the Phenotype-Genotype 
Biomarker study of the CReATe Consortium. 
 
 ALS ALS-FTD PLS PMA 
N 279 13 22 13 
Sex, Male (%) 163 (58.4) 11 (84.6) 11 (50.0) 8 (61.5) 




















Symptom Onset to Baseline 









Site of Symptom Onset, N (%)     
Bulbar 45 (17.1) 4 (33.3) 5 (22.7) - 
Bulbar & Limb 7 (2.7) - 3 (13.6) - 
Bulbar & Other 7 (2.7) 1 (8.3) - - 
Limb 175 (66.5) 3 (25) 13 (59.1) 11 (84.6) 
Limb & Other 22 (8.4) - 1 (4.5) 1 (7.7) 
Other 7 (2.7) 4 (33.3) - 1 (7.7) 










Mutation Carrier, N (%) 34 (12.2) 3 (20.0) 0 (0.0) 0 (0.0) 
C9ORF72 22 (7.9) 3 (20.0) - - 
C9ORF72 and UBQLN2 1 (0.4) - - - 
SOD1 8 (2.9) - - - 
SQSTM1 1 (0.4) - - - 
TARDBP 1 (0.4) - - - 
TBK1 1 (0.4) - - - 






























ECAS, Mean (SD)     
ALS Specific (0-100) 80.94 (10.85) 52.62 (12.07) 87.95 (7.47) 81.62 (11.61) 
Language (0-28) 25.85 (2.66) 21.38 (3.93) 26.82 (1.97) 26.62 (1.26) 
Verbal Fluency (0- 24) 16.62 (5.11) 7.83 (5.36) 26.82 (1.97) 16.77 (4.36) 
Executive (0-48) 38.47 (5.94) 24.00(10.51) 26.82 (1.97) 38.23 (7.50) 
ALS Non-Specific (0-36) 28.04 (3.78) 19.69 (8.30) 29.73 (2.76) 27.62 (6.31) 
Memory (0-24) 16.45 (3.54) 9.46 (7.15) 17.95 (2.84) 15.69 (6.20) 
Visuospatial (0- 12) 11.59 (0.79) 11.08 (1.24) 11.77 (0.43) 11.92 (0.28) 
ECAS Total (0-136) 108.97 (13.02) 72.31 (18.53) 117.68 (9.12) 109.23 (16.47) 
Abbreviations: CReATe = Clinical Research in ALS and Related Disorders for 
Therapeutic Development; PLS = Primary lateral sclerosis, PMA = Progressive 
muscular atrophy; ALSFRS-R = Revised ALS Functional Rating Scale; UMN = 
upper motor neuron; LMN = lower motor neuron; ECAS = Edinburgh Cognitive 
and Behavioral ALS Screen; SD = standard deviation 
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Table 10. Demographics of independent neuroimaging and autopsy ALS and 
control cohorts from UPenn. 
 
A. Neuroimaging Cohort 
 ALS Healthy Control 
N (Male) 114 (64) 114 (64) 
Age at MRI in Years, M (SD) 59.34 (10.92) 61.87 (12.18) 
Education in Years, M (SD) 15.09 (2.98) 15.87 (2.47) 
Disease Duration in Years, M 
(SD) 
3.02 (2.52) - 
























ALSFRS-R, M (SD) 33.23 (7.32) - 
 
 
B. Autopsy Cohort 
N (Male) 88 (49) 
Age at Death Years, M (SD) 63.72 (10.24) 
Disease Duration at Death in Years, M (SD) 4.24 (3.41) 










Abbreviations: ALSFRS-R = ALS Functional Rating Scale – Revised; M = Mean, 
SD = standard deviation 
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Proxy HG19 Position 
rs2068667 NFASC 1 0.208 chr1:204948552 rs11240317 chr1:204920322 
rs11185393 AMY1A 1 0.368 chr1:104209379 rs67205957 chr1:104752258 
rs515342 ASB1 2 0.214 chr2:238458655 rs508986 chr2:239337691 
rs9820623 MOBP 3 0.406 chr3:39452367 rs6765697 chr3:39493239 
rs13079368 MOBP 3 0.275 chr3:39471060 rs1464047 chr3:39526874 
rs1768208 MOBP 3 0.323 chr3:39481512 rs616147 chr3:39534481 
rs10463311 TNIP1 5 0.431 chr5:151031274 - - 
rs3828599 GPX3 5 0.417 chr5:151022235 rs4958872 chr5:150402334 
rs538622 ERGIC1 5 0.32 chr5:172920676 rs2446192 chr5:172352369 
rs17111695 NAF1 5 0.183 chr5:151052885 rs12518386 chr5:150438085 
rs757651 REEP2 5 0.016 chr5:138455779 rs149312547 chr5:137792021 
rs10488631 TNPO3 7 0.059 chr7:128954129 rs12539741 chr7:128596805 
rs17070492 LOC101927815 8 0.208 chr8:2563763 - - 
rs7813314 BC045738 8 0.2 chr8:2558274 rs6996532 chr8:2417678 
rs10869188 C9ORF72 9 0.49 chr9:72614090 rs7032232 chr9:75229116 
rs870901 AK097706 9 0.133 chr9:107086201 rs60743641 chr9:109854824 
rs10511816 MOBKL2B 9 0.206 chr9:27468463 rs12551344 chr9:27466817 
rs3849943 C9ORF72 9 0.183 chr9:27543384 - - 
rs3849942 C9ORF72 9 0.183 chr9:27543283 - - 
rs13302855 C9ORF72 9 0.086 chr9:27595997 rs34460171 chr9:27594491 
rs3849943 C9ORF72 9 0.183 chr9:27543384 - - 
rs732389 AK294518 10 0.205 chr10:78584745 rs7071538 chr10:80338173 
rs7118388 CAT 11 0.454 chr11:34432600 rs1962369 chr11:34456941 
rs12803540 CAT 11 0.138 chr11:34471200 rs17881488 chr11:34492443 
rs117027576 KIF5A 12 0.00913 chr12:56922819 - - 
rs113247976 KIF5A 12 0.007 chr12:57581917 - - 
rs142321490 KIF5A 12 0.006 chr12:58282349 - - 
rs74654358 TBK1 12 0.012 chr12:64488187 - - 
rs118082508 KIF5A 12 0.005 chr12:5692503 - - 
rs116900480 KIF5A 12 0.006 chr12:58262322 - - 
rs1578303 HTR2A 13 0.204 chr13:47389011 rs144877054 chr13:47962781 
rs10492593 PCDH9 13 0.121 chr13:66919985 rs73208976 chr13:67486924 
rs17446243 TTL/TEL 13 0.116 chr13:40174794 rs78375967 chr13:40751567 
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rs10139154 SCFD1 14 0.428 chr14:30678292 - - 
rs10143310 ATXN3 14 0.339 chr14:92074037 - - 
rs12886280 NUBPL 14 0.412 chr14:31829453 rs35875023 chr14:32298974 
rs6603044 BTBD1 15 0.332 chr15:83015059 rs12904695 chr15:83700365 
rs9901522 PMP22 17 0.18 chr17:14770617 - - 
rs739439 KIAA0524 17 0.105 chr17:28396803 rs35714695 chr17:26719788 
rs2240601 MSI2 17 0.192 chr17:57673751 rs16942143 chr17:55748611 
rs2285642 GGNBP2 17 0.407 chr17:36556904 rs10707226 chr17:34916453 
rs7224296 NSF 17 0.472 chr17:46722680 rs9912530 chr17:44836302 
rs12973192 UNC13A 19 0.278 chr19:17642430 - - 
rs12608932 UNC13A 19 0.43 chr19:17641880 rs12973192 chr19:17753239 
rs4239633 UNC13A 19 0.28 chr19:17631660 rs71162163 chr19:17744075 
rs75087725 C21orf72 21 0.003 chr21:44333234 - - 
Abbreviations: CReATe = Clinical Research in ALS and Related Disorders 
for Therapeutic Development; GMAF = global minor allele frequency; Chr = 
chromosome; GRCh38 = Genome Reference Consortium Human Build 38; 
HG19 = Human Genome Project 19 
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Table 12: Peak voxel coordinates for regions of reduced cortical thickness for 
ALS relative to healthy controls and associated with increased weighted 
polygenic score in patients with sporadic ALS from the independent validation 
cohort from UPenn. 
 
L/ MNI Coordinates T p 
Neuroanatomic region (BA) R x y z statistic value Voxels 
Reduced cortical thickness in ALS relative to healthy controls1: 
      <.001 42994 
Anterior cingulate cortex (32) L -2 48 10 7.2   
Dorsolateral prefrontal cortex (9) L -2 48 18 7.08   
Anterior premotor cortex (8) L -2 30 36 6.76   
Orbitofrontal cortex (11) R 8 26 -26 6.71   
Insula (13) R 40 16 -12 6.46   
Insula (13) R 36 22 4 6.37   
Anterior prefrontal cortex (10) R 26 58 0 6.32   
Insula (13) R 42 2 0 6.26   
Dorsolateral prefrontal cortex (9) R 2 48 18 6.22   
Anterior cingulate cortex (32) R 2 30 22 6   
Reduced cortical thickness associated with wPGS in ALS: 
Lateral temporal cortex (21) L -66 -46 -8 3.01 0.003 34 
Premotor cortex (6) R 36 -14 70 3.05 0.001 23 
Premotor cortex (6) L -14 -8 76 3 0.002 21 
Orbital prefrontal cortex (47) R 34 42 -8 2.67 0.005 18 
Lateral temporal cortex (21) L -66 -44 6 2.54 0.002 13 
Anterior cingulate cortex (32) R 14 40 0 2.59 0.004 13 
Hippocampus (54) L -24 -30 -8 2.74 0.004 10 
Abbreviations: BA = Brodmann area; L/R = Left/Right; MNI = Montreal 
Neurological Institute 
Note.1 Cortical regions identified from peak voxel coordinates in an effort to 
describe sub-peaks within a larger, contiguous cluster. 
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Table 13: Number of UPenn ALS autopsy cases for each neuropathological 






Middle frontal cortex Neuronal loss 87 
Middle frontal cortex TDP-43 87 
Cingulate cortex Neuronal loss 88 
Cingulate cortex TDP-43 87 
Motor cortex Neuronal loss 84 
Motor cortex TDP-43 86 
Superior / middle temporal cortex Neuronal loss 87 
Superior / middle temporal cortex TDP-43 84 
CA1 / subiculum (hippocampus) Neuronal loss 88 
CA1 / subiculum (hippocampus) TDP-43 85 




Figure 6. Clinical and genetic heterogeneity in ALS patients from the CReATe 
Phenotype-Genotype Biomarker study. A) Standard deviation from mean 
baseline performance and rate of decline on each clinical variable for each 
participant. B) Correlation matrix between baseline performance and rate of 
decline on each clinical measure across all participants. C) Categorical coding for 










































Figure 7. Gridsearch for sparse canonical correlation analysis parameters. Each 
column indicates 1 of 100 unique combinations of L1 parameters (ranging 0.1 to 
1) applied to clinical and genetic datasets, and each row lists a variable entered 
into the sCCA. The heatmap denotes the canonical weight strength between 
clinical variables and genetic variables within each column; warmer colors 































































Principal Component 1 


























Figure 8. 10,000 iterations of sparse canonical correlation analysis modeling 
using bootstrapped subsampling. Each column indicates 1 of 10,000 iterations 
from randomly-bootstrapped subsamples of 75% of participants in the CReATe 
PGB cohort, and each row lists a variable entered into the sCCA. The heatmap 
denotes the canonical weight strength for each clinical variables and genetic 
variables within each column; warmer colors indicate positive weights and cooler 



















































































Principal Component 1 












Figure 9. p value calculation for sparse canonical correlation analysis modeling. 
Histogram showing the frequency of canonical correlations achieved for sCCA 
modeling under the null hypothesis across 10,000 randomly bootstrapped sCCAs 
of randomly permuted data. The vertical turquoise line demonstrates the median 
canonical correlation achieved under sCCA modeling of the original, unpermuted 
data, and the p value is calculated as the proportion of times the median 
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Figure 10. Sparse polygenic relationship between clinical and genetic variation in 
ALS patients from the CReATe Phenotype-Genotype Biomarker study. sCCA 
selected Edinburgh Cognitive and Behavioral ALS Screen (ECAS) subscores 
and 29 genetic variables which resulted in the maximal correlation between 
clinical and genetic variates in the CReATe PGB cohort. The color key denotes 
which variables were selected for inclusion in the model: Green = selected, Gray 
= not selected. The heatmap denotes the median canonical weight associated 
with each relationship between each selected SNP and the ECAS Score, with 







Figure 11. Variables selected sparse canonical correlation analysis modeling 
using original, unpermuted data and, under the null hypothesis, randomly- 
permuted data. A) Bar graphs demonstrating the proportion of times out of 
10,000 randomly-bootstrapped sCCAs that each of the 11 clinical variables were 
selected by sCCA using randomly permuted (turquoise) and original (coral) data. 
B) Bar graphs demonstrating the number of times out of 10,000 randomly- 
bootstrapped sCCAs that each of the 45 investigated SNPs were selected by 
sCCA using randomly permuted (turquoise) and original (coral) data. SNPs are 
organized according to prior genome-wide association with ALS or joint 
















































































































































































































































































































































































































































































































































































































Figure 12. Correlation between weighted polygenic risk score and cognitive 
performance in ALS patients from the CReATe Phenotype-Genotype Biomarker 
study. Weighted polygenic risk score correlates with A) adjusted baseline 
performance on the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) 
ALS-Specific, Total, Executive Function, and Language scores, and B) rate of 
















































































































































































































































































Figure 13. Cortical thickness and neuronal loss related to weighted polygenic 
risk score in independent cohorts from UPenn. 
 
A) ALS patients (N=114) from an independent cohort at UPenn displayed 
widespread cortical thinning relative to age, sex, and education-matched healthy 
controls (N=114) in the frontal and temporal lobes. The heatmap indicates the 






B) ALS patients (N=114) from an independent cohort at UPenn with higher 
weighted polygenic risk score exhibited greater reduction of cortical thickness in 
the orbital prefrontal cortex, anterior cingulate cortex, premotor cortex, lateral 
temporal cortex, and hippocampus. The heatmap indicates the associated T- 




C) Beeswarm boxplots of ordinal neuronal loss score (0 = none/rare, 3 = severe) 
in ALS cases at autopsy from an independent cohort at UPenn (N=88) showing 
that greater ordinal neuronal loss score is associated with higher weighted 








































































































































































Research from the past several decades has demonstrated inextricable clinical, 
biologic, and genetic linkage between ALS and FTD, such that the two diseases 
are contemporarily conceptualized as occurring as clinical extremes on a 
continuous spectrum. Affected individuals experience disease onset often in 
middle age and diagnosis precedes death typically in less than 10 years. There is 
no cure for disease, and current treatments are only palliative or disease-slowing 
in nature. Despite advances in modern understanding of the cause and 
consequence of ALS-FTD spectrum disease, profound phenotypic heterogeneity 
precludes clinical prognostication and efforts for therapeutic development. 
Critically, cognition is a major source of phenotypic heterogeneity and impaired 
cognition confers increased risk for decreased functional ability during disease 
course and shorter survival. The goal of my thesis work has been to elucidate 
factors that influence cognition and underlying disease neuroanatomy in ALS- 
FTD spectrum disease, with the ultimate goal of defining prognostic markers and 
potential targets for disease-modifying therapies. In a series of three original 
research studies, I demonstrate strong environmental and genetic contribution to 
severity of cognitive impairment and frontotemporal disease neuroanatomy in 
ALS-FTD spectrum disease. 
In the first study, I show environmental contribution from lifetime cognitive 
engagement to verbal executive control and gray matter atrophy in a 
phenotypically and genetically diverse cohort of patients. Specifically, my results 
indicate that higher education and occupation – considered singly or cumulatively 
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in a cognitive reserve index – relate to reduced gray matter atrophy in right- 
lateralized prefrontal cortical regions functionally linked to executive processes, 
and relate to less impaired performance on a measure of verbal executive 
control. I further demonstrate through analysis of data from healthy controls that 
this association is specific to patients. In answer to my first research question, 
“How does lifetime cognitive engagement relate to cognition and disease 
neuroanatomy in ALS-FTD spectrum disease?”, these findings suggest that 
lifetime cognitive engagement contributes to heterogeneity of verbal executive 
control and underlying neurodegeneration in functionally-associated prefrontal 
cortical regions. 
In the second study, I demonstrate converging, multimodal evidence that 
common genetic variation at rs12608932 in UNC13A, a previously-identified risk 
locus for ALS and FTD, further contributes to frontotemporal disease in patients 
with sporadic ALS-FTD spectrum disease with initial ALS. My findings indicate 
that patients carrying the rs12608932 minor allele exhibit more severe in vivo 
cortical thinning in prefrontal, motor, and temporal cortices and greater 
impairment on a measure of working memory under both additive and recessive 
minor allele modeling. Consistent with in vivo findings, analyses in a separate 
autopsy cohort show that carriers of the rs12608932 minor allele have greater 
burden of post mortem TDP-43 pathology in the middle frontal cortex, middle 
temporal cortex, and motor cortex. In answer to my second research question, 
“Do common genetic variants that confer risk for ALS-FTD spectrum disease 
relate to cognition and disease neuroanatomy?”, my results demonstrate 
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converging multimodal evidence of contribution via common, single-allelic 
genetic variation at rs12608932 to frontotemporal disease phenotype. 
Last, in the third study, I demonstrate that common genetic variation further 
contributes to cognition and underlying disease neuroanatomy in a polygenic 
manner. Using machine learning conducted in a large, multicenter patient cohort, 
I find polygenic contribution predominantly from SNPs conferring joint risk for 
ALS and FTD to cognitive performance in ALS patients both at baseline and 
longitudinally. I derive a polygenic risk score for cognitive dysfunction based on 
these results, and show that ALS patients at higher polygenic risk have greater 
cortical atrophy in the prefrontal, premotor, and temporal cortices and the 
hippocampus. I further show in an independent autopsy cohort that ALS patients 
at higher polygenic risk demonstrate more severe neuronal loss in the motor 
cortex. In answer to the question, “Is there evidence of polygenic contribution via 
common genetic variants to cognition and disease neuroanatomy?”, this study 
provides quantitative trait evidence for polygenic contribution from common 
genetic variants to cognition and frontotemporal disease neuroanatomy in ALS- 
FTD spectrum disease. 
Collectively, this body of work aids scientific understanding of factors 
shaping heterogeneous cognitive phenotypes in ALS-FTD spectrum disease and 
offers biomarkers for actionable use in patient prognostication and clinical trials. 
In this final chapter, I now consider avenues for future research stemming from 




Limitations & Future Directions 
 
My thesis work motivates a number of avenues for future research on factors 
contributing to heterogeneous phenotypes in ALS-FTD spectrum disease and 
suggests methods applicable for similar study in other phenotypically 
heterogeneous neurodegenerative diseases. 
The work in this dissertation presents evidence in favor of strong 
contribution from both lifetime cognitive engagement and common genetic 
variation to cognition and disease neuroanatomy in ALS-FTD spectrum disease, 
leading to a subsequent line of inquiry: Do these factors interact to influence 
phenotypic heterogeneity? A few recent studies, while limited to patients with 
FTD, suggest that such interaction may occur. Presymptomatic individuals either 
positive for a pathogenic mutation in C9ORF72, MAPT, or GRN or with a strong 
familial disease history display higher premorbid frontal and total GM volume 
relating to greater educational attainment (Gazzina et al. 2019; Premi et al. 
2017); interestingly, risk genotype at a SNP near TMEM106B was found to 
enhance this relationship in mutation carriers relative to non-carriers (Premi et al. 
2017). Another study in a symptomatic FTD cohort ranging in clinical phenotypes 
and mutation status showed that risk genotype at a polymorphism near the 
SCLA4 gene magnified the association between an index of lifetime cognitive 
engagement and reduced frontal cerebral blood flow (Premi et al. 2015). With 
these findings in mind, it is reasonable to surmise that similar interactions may 
occur between lifetime cognitive engagement and common genetic variation at 
single loci or considered in a polygenic manner. This train of thought could be 
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further extended to examine potential interactions between genetic factors and 
other environmental factors not specifically associated with lifetime cognitive 
engagement, such as smoking (Sutedja et al. 2007), physical activity (Huisman 
et al. 2013), and traumatic brain injury (Kalkonde et al. 2012; Rosso, Landweer, 
et al. 2003), which have been associated with risk for ALS and FTD. In a similar 
vein, epigenetic modification of genes associated with ALS and FTD (e.g. 
C9ORF72 (McMillan et al. 2015; Russ et al. 2015)) could be also explored 
relative to environmental factors. Thus, one avenue for future work is to examine 
how environmental and genetic factors may interact or concurrently influence 
cognition and disease anatomy across ALS-FTD spectrum disease. 
A second logical extension of my thesis work regards the broader study of 
genetic factors. I limited my investigation of common genetic variants in my 
thesis work to loci previously identified as conferring risk for ALS and FTD to 
explore quantitative-trait relationships with cognition and disease anatomy in a 
hypothesis-driven manner. However, in recent years, whole-genome sequencing 
has become increasingly cost-effective and technological advances have 
enabled greater computational efficiency for the analysis of extremely large data 
sets (e.g. 3.2 billion reads from ~38x genome coverage). Another interesting 
avenue for further study is thus the study of the whole genome relative to 
cognition and neuroanatomy in ALS-FTD spectrum disease. For example, 
sparse, machine learning approaches like sCCA could investigate genotype- 
phenotype relationships between a dataset comprising whole genome 
sequencing and a dataset comprising quantitative phenotypic characterization 
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(e.g. neuropsychological evaluation, voxel-wise neuroimaging data). Some 
intriguing and innovative research studies over the past decade from the 
Alzheimer’s disease literature offer insight into the potential use of genome-wide 
data relative to complex quantitative phenotypes. These include the development 
of a voxel-wise GWAS techniques designed to identify genetic loci associated 
with regional heterogeneity in structural neuroimaging these methods has been 
applied to identify both SNP-based and gene-based loci associated with brain 
volume in healthy elderly participants and mixed cohorts of controls and patients 
from ADNI (Stein et al. 2010; Hibar et al. 2011). More recent studies from the 
Alzheimer’s disease literature also describe techniques for analyzing genome- 
wide data relative to neuropathological categorization and relative to clinical 
phenotypic variation (Beecham et al. 2014; Moreno-Grau et al. 2019). It is 
therefore not unreasonable to suggest these techniques could be adopted to the 
study of genetic factors influencing heterogeneity in cognition and disease 
anatomy, ascertained through multiple modalities including neuropsychological 
evaluation, neuroimaging, and post mortem neuropathological examination, in 
ALS-FTD spectrum disease. 
A third extension of the work presented here concerns the expansion of 
data sources and the methods used to analyze them. Based on my defined 
research questions, I chose to study data from symptomatic patients with ALS- 
FTD spectrum disease and to use specific nonparametric and machine learning 
methods. Other data sources, including from biofluid biomarkers (Benatar, 
Turner, and Wuu 2019; van der Ende et al. 2019) and functional neuroimaging 
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(Ferraro et al. 2018; Olm et al. 2018; Mutsaerts et al. 2019), reflect disease 
processes in presymptomatic individuals with familial disease history or genetic 
mutations. For example, serum and CSF levels of phosphorylated neurofilament 
heavy (pNfH) and neurofilament light (NfL) increase longitudinally in advance of 
clinically manifest ALS (Benatar et al. 2019). A potential future line of research 
could thus investigate environmental and genetic factors relative to cognition and 
frontotemporal disease anatomy in presymptomatic individuals. Results from this 
proposed research in presymptomatic ALS-FTD could then be subsequently 
investigated in symptomatic patient cohorts, with analyses stratified for mutation- 
negative and sporadic forms of disease. In addition to data sources reflecting 
early disease stage, my thesis work could be extended to utilize other 
unsupervised machine learning methods to identify genetic factors associated 
with disease. These include methods integrating prior knowledge (e.g. GWAS 
effect sizes for loci associated with disease risk) into model estimates (Blatti et al. 
2020), and methods designed to identify quantitative trait loci associated with 
data collected from patients with different disease groups (H. Wang et al. 2012). 
In the context of ALS-FTD spectrum disease, such machine learning methods 
could be used to integrate effect sizes from ALS and FTD GWAS into model 
estimates of genetic risk for impaired cognition, and to identify loci associated 
with multiple phenotypes (e.g. identify loci associated with impaired cognition and 
frontotemporal atrophy). 
A final avenue for future research stems from the ubiquitous need for 
independent replication of scientific findings, including those presented in the 
146 
 
current body of work. As noted in the introduction, I have endeavored to adopt 
robust statistical approaches including the incorporation of multiple modalities in 
an attempt to validate my findings across datasets, given the absence at the time 
of study of additional, independent cohorts sufficient data necessary for true 
replication. I have incorporated analysis of complementary, independent datasets 
(e.g. from ADNI, the CReATe Consortium, and the UPenn Integrated 
Neurodegenerative Disease Biobank) to evaluate null hypothesis in control 
cohorts and seek converging evidence from additional biomarkers for my results, 
when possible. Tremendous efforts for multicenter, cross-institutional, and 
international observational research studies have been made through the recent 
formation of entities including the CReATe consortium and the ARTFL–LEFFTDS 
Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) research consortium 
(H. J. Rosen, Boeve, and Boxer 2020). True replication of the environmental and 
genetic influence on cognition and disease anatomy that I demonstrate through 
my work will likely only be accomplished through continued support for and 
research participation in these, and other, collaborative endeavors. 
 
 
Conclusions and Implications for the Field 
 
The research studies I have pursued for my thesis addressed the critical clinical 
need for the identification of factors influencing heterogeneity in cognition and 
disease anatomy in ALS-FTD spectrum disease. The availability of rich, 
multimodal data from large patient cohorts was critical to my study design and to 
the strength of evidence I was able to present in support of robust contribution 
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from environmental and genetic factors to cognition and underlying disease 
anatomy in ALS-FTD spectrum disease. 
My thesis work holds implications for future advancements in clinical care and 
therapeutic development and stimulates further research. The environmental and 
genetic factors elucidated through my research hold potential to improve 
prognostication in clinical care and therapeutic development with appropriate 
validation. Routine patient genotyping, generated through a minimally-invasive 
procedure in an increasingly cost-effective manner, may be used to investigate 
pharmaco-genomic interactions in ongoing clinical trials. Patient genotyping and 
measures of lifetime cognitive engagement (e.g. education and occupation) could 
further be used to stratify patients in clinical trials to alleviate potential confounds 
associated with the profound phenotypic heterogeneity observed in ALS-FTD 
spectrum disease. In addition to stratification, environmental and genetic factors 
might also serve as potential therapeutic targets. For example, cognitive 
engagement and associated frontal cortical function might be targeted early in 
disease course through digital (e.g. smartphone applications) or neuromodulatory 
(e.g. transcranial direct current stimulation) strategies. With these clinical and 
therapeutic implications in mind, my work stimulates future research on genetic 
and environmental factors influencing heterogeneity in patient phenotype. My 
work has demonstrated the critical utility of large, multimodal datasets in 
elucidating disease-modifying factors, and accordingly implicates that further 
support and maintenance of collaborative data-collection on patient populations 
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